k141_87560_4	SARG|gb|AAK76136.1|ARO:3000025|patB	32.6	585	587	588	1.06e-99	313
k141_87560_4	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.5	510	587	664	1.92e-94	302
k141_87560_4	SARG|gb|CDO61516.1|ARO:3003949|efrB	44.6	323	587	362	3.25e-86	271
k141_87560_4	SARG|gi|860594225|ref|WP_048475168.1|	29.9	576	587	620	3.48e-83	271
k141_87560_4	SARG|gi|948137056|ref|WP_056795395.1|	29.7	583	587	602	2.64e-80	263
k141_87560_4	SARG|gi|664556405|ref|WP_031071225.1|	30.0	580	587	602	3.70e-80	263
k141_87560_4	SARG|gi|772774655|ref|WP_045322518.1|	29.4	582	587	620	3.99e-80	263
k141_87560_4	SARG|gi|944152509|ref|WP_055644808.1|	29.9	572	587	616	5.10e-80	263
k141_87560_4	SARG|gi|1033217078|gb|OAR27197.1|	29.1	577	587	601	7.07e-80	262
k141_87560_4	SARG|gi|928900436|ref|WP_053931243.1|	29.1	571	587	600	9.66e-80	261
k141_87560_5	SARG|gb|WP_104671188.1|ARO:3003948|efrA	37.9	560	597	575	2.08e-117	359
k141_87560_5	SARG|gb|AAK76137.1|ARO:3000024|patA	32.4	586	597	564	1.92e-91	291
k141_87560_5	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.1	576	597	582	4.50e-64	219
k141_87560_5	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	27.1	598	597	579	2.86e-58	204
k141_87560_5	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	27.9	595	597	579	2.79e-57	201
k141_87560_5	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	31.6	396	597	574	1.15e-53	191
k141_87560_5	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.9	505	597	664	1.18e-52	190
k141_87560_5	SARG|gb|AAK76136.1|ARO:3000025|patB	27.2	503	597	588	1.91e-52	188
k141_87560_5	SARG|gi|662754041|ref|WP_030125200.1|	32.3	378	597	601	1.90e-49	180
k141_87560_5	SARG|gi|1045390184|ref|WP_065479071.1|	30.9	379	597	605	3.48e-48	176
k141_87560_20	SARG|gi|1004359922|gb|AMP42228.1|	26.0	434	604	639	7.94e-28	117
k141_87560_20	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.4	435	604	629	3.22e-27	115
k141_87560_20	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.4	435	604	629	3.22e-27	115
k141_87560_20	ResF|tet(O/W)_3_AM889120_1	26.4	435	604	639	3.34e-27	115
k141_87560_20	ResF|tet(O/W)_4_AM889121_1	26.4	435	604	639	3.34e-27	115
k141_87560_20	SARG|ABV82118	23.0	435	604	639	5.93e-27	114
k141_87560_20	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.4	435	604	629	7.62e-27	114
k141_87560_20	ResF|tet(O/W)_5_AM889122_1	26.4	435	604	639	7.90e-27	114
k141_87560_20	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.2	435	604	629	1.35e-26	113
k141_87560_20	SARG|AAY62597	26.2	435	604	639	1.40e-26	113
k141_8111_27	SARG|gi|696368937|ref|WP_032943949.1|	38.6	220	252	648	4.90e-41	147
k141_8111_27	SARG|gi|851913025|ref|WP_048215946.1|	38.6	220	252	648	4.90e-41	147
k141_8111_27	SARG|gi|489930965|ref|WP_003834285.1|	38.6	220	252	648	4.90e-41	147
k141_8111_27	SARG|gi|936194420|ref|WP_054528571.1|	38.6	220	252	648	6.75e-41	147
k141_8111_27	SARG|gi|851922185|ref|WP_048218206.1|	38.6	220	252	648	6.75e-41	147
k141_8111_27	SARG|gi|949718947|ref|WP_057063453.1|	38.6	220	252	648	6.75e-41	147
k141_8111_27	SARG|gi|696375069|ref|WP_032949617.1|	38.6	220	252	648	6.75e-41	147
k141_8111_27	SARG|gi|696361545|ref|WP_032936694.1|	38.6	220	252	648	6.75e-41	147
k141_8111_27	SARG|gi|489936909|ref|WP_003840216.1|	38.6	220	252	648	6.75e-41	147
k141_8111_27	SARG|gi|489127020|ref|WP_003036815.1|	38.6	220	252	648	6.75e-41	147
k141_63695_7	NCBI|WP_063856927.1|1|1|vanZ-Pt|vanZ-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ-Pt|AMR|glycopeptide	44.4	99	162	159	3.35e-16	70.5
k141_63695_7	SARG|gi|515720450|ref|WP_017153050.1|	39.5	81	162	210	4.57e-11	57.8
k141_63695_7	SARG|AF155139.2.gene5.p01	44.0	75	162	206	4.22e-10	55.1
k141_71702_4	SARG|gb|AAK76136.1|ARO:3000025|patB	32.1	613	645	588	6.85e-100	316
k141_71702_4	SARG|gb|AYV52072.1|ARO:3002882|lmrD	32.7	548	645	664	3.71e-92	298
k141_71702_4	SARG|gi|951183771|ref|WP_057661487.1|	32.0	553	645	603	1.70e-85	278
k141_71702_4	SARG|gi|497748188|ref|WP_010062372.1|	31.6	553	645	605	1.78e-85	278
k141_71702_4	SARG|gi|944009777|ref|WP_055601444.1|	31.2	618	645	628	3.09e-85	278
k141_71702_4	SARG|gi|695891735|ref|WP_032792824.1|	31.6	553	645	603	6.51e-85	277
k141_71702_4	SARG|gi|664170108|ref|WP_030704355.1|	32.2	553	645	603	9.10e-85	276
k141_71702_4	SARG|gi|913055317|ref|WP_050357634.1|	31.6	553	645	603	9.10e-85	276
k141_71702_4	SARG|gi|764446018|ref|WP_044369325.1|	31.3	553	645	605	9.55e-85	276
k141_71702_4	SARG|gi|664180077|ref|WP_030714054.1|	31.6	553	645	605	9.55e-85	276
k141_71702_5	SARG|gb|AAK76137.1|ARO:3000024|patA	48.6	70	80	564	1.35e-15	68.6
k141_71702_5	SARG|gb|WP_104671188.1|ARO:3003948|efrA	47.7	65	80	575	6.44e-15	66.6
k141_71702_5	SARG|gi|860594225|ref|WP_048475168.1|	43.1	58	80	620	9.26e-10	52.0
k141_71702_5	SARG|gi|664352659|ref|WP_030880307.1|	44.8	58	80	601	3.23e-09	50.4
k141_71702_5	SARG|gi|662754041|ref|WP_030125200.1|	44.8	58	80	601	3.23e-09	50.4
k141_71702_5	SARG|gi|664100597|ref|WP_030638327.1|	44.8	58	80	601	3.23e-09	50.4
k141_71702_5	SARG|gi|505389066|ref|WP_015576168.1|	44.8	58	80	601	3.23e-09	50.4
k141_71702_5	SARG|gi|517347347|ref|WP_018522839.1|	39.4	66	80	601	3.23e-09	50.4
k141_71702_5	SARG|gi|503923650|ref|WP_014157644.1|	44.8	58	80	601	3.23e-09	50.4
k141_71702_5	SARG|gi|953808775|ref|WP_058042812.1|	38.8	67	80	608	3.23e-09	50.4
k141_40184_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	32.3	232	336	255	7.66e-30	113
k141_40184_2	SARG|gi|1033064422|ref|WP_064375412.1|	32.6	230	336	648	5.03e-28	113
k141_40184_2	SARG|Q83LR7	34.8	230	336	648	6.81e-28	113
k141_40184_2	SARG|gi|647325472|ref|WP_025760953.1|	34.8	230	336	648	6.81e-28	113
k141_40184_2	SARG|gi|647323678|ref|WP_025760497.1|	34.8	230	336	648	6.81e-28	113
k141_40184_2	SARG|gi|446110305|ref|WP_000188160.1|	34.3	230	336	648	1.69e-27	112
k141_40184_2	SARG|gi|1032819400|ref|WP_064325534.1|	33.5	230	336	646	4.18e-27	110
k141_40184_2	SARG|gi|851931792|ref|WP_048222288.1|	34.5	232	336	646	5.65e-27	110
k141_40184_2	SARG|gi|798937928|ref|WP_045908399.1|	34.5	232	336	646	5.65e-27	110
k141_40184_2	SARG|gi|695748190|ref|WP_032674455.1|	34.1	232	336	646	7.65e-27	110
k141_79880_5	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	25.6	199	336	550	2.38e-10	60.5
k141_79880_6	SARG|gi|1016275448|gb|AMX06027.1|	29.6	250	393	646	3.24e-18	85.5
k141_79880_6	SARG|gi|779866095|ref|WP_045354445.1|	29.2	250	393	646	1.38e-17	83.6
k141_79880_6	SARG|gi|779956086|ref|WP_045403603.1|	29.2	250	393	646	1.85e-17	83.2
k141_79880_6	SARG|gi|695731723|ref|WP_032658224.1|	29.2	250	393	646	2.47e-17	82.8
k141_79880_6	SARG|gi|1016942913|ref|WP_063144441.1|	29.2	250	393	646	2.47e-17	82.8
k141_79880_6	SARG|gi|835749851|ref|WP_047648187.1|	29.2	250	393	646	2.47e-17	82.8
k141_79880_6	SARG|gi|697052471|ref|WP_033145077.1|	29.2	250	393	646	2.47e-17	82.8
k141_79880_6	SARG|gi|695722592|ref|WP_032649220.1|	29.2	250	393	646	2.47e-17	82.8
k141_79880_6	SARG|gi|895868403|ref|WP_048976842.1|	29.2	250	393	646	2.47e-17	82.8
k141_79880_6	SARG|gi|658546960|ref|WP_029739484.1|	29.2	250	393	646	2.47e-17	82.8
k141_103960_14	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.8	363	579	582	1.81e-53	190
k141_103960_14	SARG|gi|860594225|ref|WP_048475168.1|	36.9	301	579	620	5.54e-51	184
k141_103960_14	SARG|gi|664100597|ref|WP_030638327.1|	42.4	236	579	601	3.92e-50	181
k141_103960_14	SARG|gi|505389066|ref|WP_015576168.1|	42.9	240	579	601	3.92e-50	181
k141_103960_14	SARG|gi|503923650|ref|WP_014157644.1|	42.4	236	579	601	3.92e-50	181
k141_103960_14	SARG|gi|926351744|ref|WP_053683383.1|	35.0	343	579	648	5.45e-50	182
k141_103960_14	SARG|gi|655401130|ref|WP_028800283.1|	36.6	292	579	599	7.21e-50	181
k141_103960_14	SARG|gi|662754041|ref|WP_030125200.1|	42.5	240	579	601	1.02e-49	180
k141_103960_14	SARG|gi|930482089|ref|WP_054228897.1|	42.0	238	579	599	1.36e-49	180
k141_103960_14	SARG|gi|985844137|ref|WP_060895163.1|	42.0	238	579	599	1.36e-49	180
k141_63965_6	SARG|gb|AAC75314.1|ARO:3003578|pmrF	27.4	314	327	322	1.22e-34	127
k141_48401_5	SARG|ZP_02635322	29.5	295	293	304	3.94e-33	122
k141_48401_5	SARG|ZP_02865688	29.2	295	293	304	1.07e-32	121
k141_48401_5	SARG|YP_002929946	28.2	291	293	282	1.84e-32	120
k141_48401_5	SARG|YP_695835	29.8	295	293	304	2.10e-32	120
k141_48401_5	SARG|YP_002847905	29.7	286	293	272	4.04e-32	119
k141_48401_5	SARG|ZP_04637931	29.7	286	293	269	7.39e-32	118
k141_48401_5	SARG|Q57JQ4	30.1	286	293	273	1.13e-31	117
k141_48401_5	SARG|YP_218139	30.1	286	293	274	1.15e-31	117
k141_48401_5	SARG|YP_001590162	30.1	286	293	270	2.07e-31	117
k141_48401_5	SARG|ZP_02631430	29.2	295	293	304	2.16e-31	117
k141_32751_6	megares|MEG_5776|Drugs|Lipopeptide|Lipid_A_phosphatase|PGBB_1	29.6	179	188	236	2.99e-08	50.8
k141_32751_6	SARG|gb|BAG33043.1|ARO:3003920|pgpB	29.4	177	188	236	4.08e-08	50.4
k141_48439_46	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.5	499	519	655	3.18e-84	273
k141_48439_46	SARG|gb|AKA86814|ARO:3003746|optrA	33.5	499	519	655	3.18e-84	273
k141_48439_46	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.5	499	519	655	8.73e-84	271
k141_48439_46	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.5	499	519	655	8.73e-84	271
k141_48439_46	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.5	499	519	655	8.73e-84	271
k141_48439_46	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.5	499	519	655	1.22e-83	271
k141_48439_46	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.5	499	519	655	1.22e-83	271
k141_48439_46	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.5	499	519	655	1.71e-83	271
k141_48439_46	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.5	499	519	655	2.40e-83	270
k141_48439_46	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	499	519	655	6.58e-83	269
k141_48439_47	SARG|ZP_03958019	55.2	297	300	317	1.22e-105	309
k141_48439_47	SARG|ZP_04528247	55.1	301	300	279	7.96e-105	306
k141_48439_47	SARG|YP_002929946	56.1	301	300	282	8.24e-103	301
k141_48439_47	SARG|YP_002937728	57.1	294	300	289	2.97e-102	300
k141_48439_47	SARG|ZP_04433866	47.3	292	300	288	2.84e-79	241
k141_48439_47	SARG|ZP_03949893	47.3	292	300	288	2.84e-79	241
k141_48439_47	SARG|ZP_03984017	46.9	292	300	288	5.70e-79	240
k141_48439_47	SARG|ZP_03945515	46.2	299	300	291	1.84e-75	231
k141_48439_47	SARG|ZP_03938934	45.7	300	300	288	3.82e-74	228
k141_48439_47	SARG|ZP_03941859	45.3	300	300	288	3.06e-73	226
k141_120112_1	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	29.8	248	403	355	1.99e-19	87.8
k141_120112_1	SARG|BAE96115	29.8	248	403	355	1.99e-19	87.8
k141_120112_1	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.9	244	403	355	4.95e-19	86.7
k141_120112_1	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	29.9	244	403	355	4.95e-19	86.7
k141_120112_1	SARG|ACM47285	29.9	244	403	363	5.34e-19	86.7
k141_8917_3	SARG|gi|851928593|ref|WP_048220996.1|	24.6	268	308	660	4.64e-11	62.4
k141_8917_3	SARG|gi|1002399350|ref|WP_061382108.1|	24.6	268	308	660	1.48e-10	60.8
k141_8917_3	SARG|gi|757799830|ref|WP_043017032.1|	24.6	268	308	660	1.98e-10	60.5
k141_8917_3	SARG|YP_002850217	24.3	268	308	660	3.53e-10	59.7
k141_8917_3	SARG|gi|851935911|ref|WP_048224705.1|	24.3	268	308	660	3.53e-10	59.7
k141_8917_3	SARG|gi|851965596|ref|WP_048234849.1|	24.3	268	308	660	3.53e-10	59.7
k141_8917_3	SARG|gi|507083067|ref|WP_016153816.1|	24.3	268	308	660	3.53e-10	59.7
k141_8917_3	SARG|gi|507086291|ref|WP_016157032.1|	24.3	268	308	660	3.53e-10	59.7
k141_8917_3	SARG|gi|696369048|ref|WP_032944060.1|	24.3	268	308	660	3.53e-10	59.7
k141_8917_3	SARG|gi|489931383|ref|WP_003834702.1|	24.3	268	308	660	3.53e-10	59.7
k141_96206_12	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	25.2	326	371	397	2.38e-09	57.4
k141_96206_27	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	36.8	247	247	255	4.36e-44	148
k141_96206_27	SARG|gi|555271393|ref|WP_023251561.1|	38.3	230	247	648	1.16e-41	149
k141_96206_27	SARG|gi|554922094|ref|WP_023194682.1|	38.3	230	247	648	1.16e-41	149
k141_96206_27	SARG|Q57R58	38.3	230	247	648	5.78e-41	147
k141_96206_27	SARG|gb|ADZ12699.1|ARO:3005091|RanA	32.8	238	247	258	8.97e-41	139
k141_96206_27	SARG|gi|696411918|ref|WP_032982657.1|	36.8	228	247	647	3.90e-40	145
k141_25013_9	SARG|gi|500194536|ref|WP_011867743.1|	29.2	288	300	306	1.33e-32	121
k141_25013_9	SARG|gi|445996722|ref|WP_000074577.1|	31.7	230	300	309	1.97e-32	120
k141_25013_9	SARG|gi|445996723|ref|WP_000074578.1|	31.7	230	300	309	2.75e-32	120
k141_25013_9	SARG|gi|445996710|ref|WP_000074565.1|	30.9	230	300	309	3.84e-32	120
k141_25013_9	SARG|gi|542061059|gb|ERI11611.1|	31.4	220	300	316	4.41e-32	120
k141_25013_9	SARG|P42332	29.2	305	300	306	5.04e-32	119
k141_25013_9	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	29.2	305	300	306	5.04e-32	119
k141_25013_9	SARG|gi|445996719|ref|WP_000074574.1|	31.3	230	300	309	5.35e-32	119
k141_25013_9	SARG|gi|445996724|ref|WP_000074579.1|	31.3	230	300	309	5.35e-32	119
k141_25013_9	SARG|gi|884875933|emb|CKG93789.1|	31.3	230	300	309	5.35e-32	119
k141_104458_7	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	24.4	275	485	593	5.11e-12	67.0
k141_104458_8	ResF|penA_1_AF515059_1	34.7	95	94	581	3.41e-13	62.4
k141_41175_5	CARD|gb|ABD30512.1|ARO:3000839|arlS	26.4	288	536	451	2.92e-31	125
k141_41175_5	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.5	302	536	381	7.01e-29	117
k141_41175_5	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.5	302	536	381	7.01e-29	117
k141_41175_5	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.4	284	536	370	3.76e-28	114
k141_41175_5	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.4	235	536	381	6.97e-27	111
k141_41175_5	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.4	235	536	381	6.97e-27	111
k141_41175_5	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	23.4	286	536	365	1.63e-22	98.2
k141_41175_5	CARD|gb|ACM47284.1|ARO:3002934|vanS_in_vanD_cl	28.7	87	536	233	5.66e-08	52.8
k141_41175_5	megares|MEG_7508|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.7	87	536	233	5.66e-08	52.8
k141_41175_5	megares|MEG_7510|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.9	86	536	233	1.84e-07	51.2
k141_41175_6	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.1	225	227	231	1.30e-52	168
k141_41175_6	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.6	227	227	232	1.34e-52	168
k141_41175_6	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.6	227	227	232	1.34e-52	168
k141_41175_6	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.3	224	227	219	4.13e-51	164
k141_41175_6	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	38.1	231	227	232	1.21e-50	163
k141_41175_6	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	34.6	228	227	229	3.18e-47	154
k141_41175_6	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.2	231	227	235	3.77e-47	154
k141_41175_6	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	35.3	232	227	239	9.46e-46	151
k141_41175_6	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.1	227	227	231	1.51e-45	150
k141_41175_6	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.1	227	227	231	8.49e-45	148
k141_25126_3	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	43.1	225	234	225	3.47e-61	190
k141_25126_3	CARD|gb|AAC73788.1|ARO:3003841|kdpE	43.1	225	234	225	3.47e-61	190
k141_25126_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.6	224	234	231	3.78e-45	149
k141_25126_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.9	222	234	219	2.68e-42	142
k141_25126_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.2	228	234	232	2.39e-40	137
k141_25126_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	31.9	226	234	232	1.88e-39	135
k141_25126_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	31.9	226	234	232	1.88e-39	135
k141_25126_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.8	223	234	228	9.40e-39	133
k141_25126_3	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	33.8	228	234	235	2.25e-38	132
k141_25126_3	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	34.5	226	234	233	3.00e-38	132
k141_25126_4	CARD|gb|CYF42523.1|ARO:3004047|kdpD	31.2	606	608	885	7.13e-86	285
k141_25126_4	SARG|gb|AAG05187.1|ARO:3005067|ParS	25.9	224	608	428	2.51e-14	74.3
k141_104678_3	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	32.0	125	299	291	4.17e-09	55.5
k141_104678_3	CARD|gb|CAA79966.1|ARO:3003665|NmcR	32.5	114	299	295	2.67e-06	47.0
k141_89315_7	SARG|YP_302230	23.7	312	441	451	6.40e-08	53.5
k141_89315_8	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	39.7	239	254	255	3.58e-51	166
k141_89315_8	SARG|gi|851928815|ref|WP_048221086.1|	42.0	224	254	648	3.82e-50	172
k141_89315_8	SARG|gi|780033092|ref|WP_045444768.1|	42.0	224	254	648	3.82e-50	172
k141_89315_8	SARG|gi|555268037|ref|WP_023249477.1|	39.4	259	254	648	1.02e-49	171
k141_89315_8	SARG|gi|960873409|ref|WP_058345546.1|	40.5	247	254	648	1.02e-49	171
k141_89315_8	SARG|gi|924626178|ref|WP_053530123.1|	39.4	259	254	648	1.41e-49	171
k141_89315_8	SARG|gi|757782629|ref|WP_043001213.1|	41.5	224	254	648	2.71e-49	170
k141_89315_8	SARG|YP_001571041	41.9	227	254	648	2.71e-49	170
k141_89315_8	SARG|gi|763407609|ref|WP_044264203.1|	41.5	224	254	648	2.71e-49	170
k141_89315_8	SARG|gi|695840638|ref|WP_032753940.1|	42.0	224	254	646	3.68e-49	170
k141_89315_11	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.2	226	223	231	2.35e-46	152
k141_89315_11	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.2	226	223	231	2.35e-46	152
k141_89315_11	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.4	226	223	231	2.64e-45	149
k141_89315_11	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.6	226	223	231	3.74e-45	149
k141_89315_11	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.4	228	223	232	5.43e-45	149
k141_89315_11	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.4	228	223	232	5.43e-45	149
k141_89315_11	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.3	226	223	231	1.05e-44	148
k141_89315_11	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.7	226	223	231	1.05e-44	148
k141_89315_11	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	35.8	229	223	233	3.51e-43	144
k141_89315_11	SARG|ZP_02848503	36.7	218	223	221	2.00e-42	142
k141_89315_12	SARG|gi|488156254|ref|WP_002227462.1|	20.5	400	464	459	9.07e-14	72.0
k141_89315_12	SARG|gi|488158065|ref|WP_002229273.1|	21.7	397	464	459	1.21e-13	71.6
k141_89315_12	NCBI|EFF39147.1|1|1|norM-NG|norM-NG|efflux|1|EFFLUX|EFFLUX|sodium-coupled_multidrug_efflux_MATE_transporter_NorM|AMR|efflux	21.1	394	464	459	2.13e-13	70.9
k141_89315_12	SARG|NC_011035.1.6448920.p01	21.1	394	464	459	2.13e-13	70.9
k141_89413_5	SARG|gi|445996719|ref|WP_000074574.1|	33.6	223	293	309	1.19e-32	121
k141_89413_5	SARG|gi|445996723|ref|WP_000074578.1|	33.2	223	293	309	1.71e-31	118
k141_89413_5	SARG|gi|445996722|ref|WP_000074577.1|	32.7	223	293	309	2.39e-31	117
k141_89413_5	SARG|gi|1043490477|ref|WP_065382463.1|	32.7	223	293	309	4.65e-31	117
k141_89413_5	SARG|gi|445996726|ref|WP_000074581.1|	32.7	223	293	309	4.65e-31	117
k141_89413_5	SARG|gi|884875933|emb|CKG93789.1|	32.3	223	293	309	4.65e-31	117
k141_89413_5	SARG|gi|507054395|ref|WP_016125339.1|	32.7	223	293	309	4.65e-31	117
k141_89413_5	SARG|gi|445996724|ref|WP_000074579.1|	32.3	223	293	309	6.48e-31	116
k141_89413_5	SARG|gi|445996729|ref|WP_000074584.1|	32.7	223	293	309	9.03e-31	116
k141_89413_5	SARG|gi|895736250|emb|COF64653.1|	32.7	223	293	309	9.03e-31	116
k141_89413_6	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	34.7	213	288	343	2.05e-27	107
k141_89413_6	SARG|gi|1035670474|ref|WP_064517458.1|	30.8	253	288	648	5.35e-24	100
k141_89413_6	SARG|gi|502669352|ref|WP_012905216.1|	32.6	224	288	648	5.35e-24	100
k141_89413_6	SARG|gi|1035717981|ref|WP_064557480.1|	30.8	253	288	648	5.35e-24	100
k141_89413_6	SARG|gi|803568669|ref|WP_046077412.1|	31.7	208	288	648	1.49e-22	96.3
k141_89413_6	SARG|gi|446110352|ref|WP_000188207.1|	31.7	208	288	648	1.49e-22	96.3
k141_89413_6	SARG|YP_002382193	31.7	208	288	648	1.49e-22	96.3
k141_89413_6	SARG|gi|803575554|ref|WP_046081557.1|	31.7	208	288	648	1.49e-22	96.3
k141_89413_6	SARG|gi|446110351|ref|WP_000188206.1|	31.7	208	288	648	1.49e-22	96.3
k141_89413_6	SARG|gb|AAK76137.1|ARO:3000024|patA	28.5	221	288	564	2.46e-22	95.5
k141_89413_11	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	29.3	372	513	373	5.74e-30	119
k141_89454_3	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	50.9	163	164	159	5.80e-52	162
k141_65245_3	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	30.6	516	581	579	7.22e-71	237
k141_65245_3	SARG|gb|AAC74000.1|ARO:3003950|msbA	33.6	521	581	582	7.91e-70	234
k141_65245_3	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	30.2	516	581	579	2.05e-68	231
k141_65245_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	31.4	523	581	664	1.93e-61	214
k141_65245_3	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	30.8	504	581	579	4.17e-61	211
k141_65245_3	SARG|gi|1045390184|ref|WP_065479071.1|	28.7	522	581	605	4.82e-60	209
k141_65245_3	SARG|gi|490068471|ref|WP_003970646.1|	29.1	522	581	603	8.93e-60	208
k141_65245_3	SARG|gi|664170108|ref|WP_030704355.1|	29.1	522	581	603	1.71e-59	207
k141_65245_3	SARG|gi|501350226|ref|WP_012381861.1|	29.1	522	581	603	1.71e-59	207
k141_65245_3	SARG|gi|497748188|ref|WP_010062372.1|	28.9	522	581	605	1.78e-59	207
k141_81158_26	CARD|gb|AAC75429.1|ARO:3000833|evgS	33.6	116	227	1197	1.13e-14	71.6
k141_81158_26	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	28.7	129	227	359	5.16e-10	57.4
k141_89641_4	NCBI|AAD44693.1|1|1|mtrA_Ngon|mtrA_Ngon||1|EFFLUX|EFFLUX|efflux_transporter_MtrCDE_transcriptional_activator_MtrA|AMR|efflux	24.2	165	288	301	3.28e-07	49.7
k141_89641_14	CARD|gb|ALH22601.1|ARO:3000620|adeL	30.6	124	295	337	9.06e-08	51.6
k141_57449_4	CARD|gb|ALH22601.1|ARO:3000620|adeL	26.1	272	299	337	8.59e-14	69.7
k141_65518_29	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	38.5	78	133	568	2.92e-09	52.8
k141_97125_5	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	45.4	1013	1073	1033	0.0	922
k141_97125_5	SARG|gb|AEY83581|ARO:3000510|mupB	45.4	1013	1073	1033	0.0	922
k141_97125_5	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	43.1	1056	1073	1024	5.61e-319	909
k141_97125_5	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	43.1	1056	1073	1024	5.61e-319	909
k141_97125_5	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	44.4	1007	1073	1024	1.03e-316	904
k141_97125_5	SARG|gb|CAA53189|ARO:3000521|mupA	44.4	1007	1073	1024	1.03e-316	904
k141_97125_5	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	35.1	1108	1073	1107	1.88e-212	639
k141_97125_5	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	35.1	1108	1073	1107	1.88e-212	639
k141_57773_2	SARG|gi|500194536|ref|WP_011867743.1|	35.3	221	363	306	3.20e-25	102
k141_57773_2	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	27.4	212	363	579	1.72e-15	76.6
k141_97279_5	SARG|gi|754724054|ref|WP_042095806.1|	40.9	230	248	648	2.28e-54	184
k141_97279_5	SARG|gi|693238509|ref|WP_032348033.1|	40.9	230	248	648	2.28e-54	184
k141_97279_5	SARG|gi|485870849|ref|WP_001467831.1|	40.9	230	248	648	2.28e-54	184
k141_97279_5	SARG|gi|979505419|ref|WP_059334195.1|	40.9	230	248	648	3.17e-54	183
k141_97279_5	SARG|ZP_04001960	40.9	230	248	648	3.17e-54	183
k141_97279_5	SARG|gi|545164255|ref|WP_021518974.1|	40.9	230	248	648	3.17e-54	183
k141_97279_5	SARG|gi|979422229|ref|WP_059319814.1|	40.9	230	248	648	3.17e-54	183
k141_97279_5	SARG|gi|1001782895|ref|WP_061321573.1|	40.9	230	248	648	3.17e-54	183
k141_97279_5	SARG|gi|754731641|ref|WP_042100724.1|	40.9	230	248	648	3.17e-54	183
k141_97279_5	SARG|gi|754637749|ref|WP_042024023.1|	40.9	230	248	648	3.17e-54	183
k141_34429_3	SARG|gi|445996719|ref|WP_000074574.1|	37.4	230	238	309	1.19e-40	140
k141_34429_3	SARG|gi|500448961|gb|EOP61695.1|	36.5	230	238	306	1.57e-40	140
k141_34429_3	SARG|gi|500194536|ref|WP_011867743.1|	37.9	227	238	306	1.57e-40	140
k141_34429_3	SARG|gi|447195835|ref|WP_001273091.1|	36.1	227	238	306	1.57e-40	140
k141_34429_3	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	36.4	220	238	307	1.60e-40	140
k141_34429_3	SARG|gi|507055561|ref|WP_016126482.1|	37.0	230	238	309	2.36e-40	139
k141_34429_3	SARG|gi|445996710|ref|WP_000074565.1|	37.0	230	238	309	2.36e-40	139
k141_34429_3	SARG|gi|507050365|ref|WP_016121371.1|	37.0	230	238	309	3.32e-40	139
k141_34429_3	SARG|gi|507044560|ref|WP_016115614.1|	35.2	230	238	306	4.35e-40	139
k141_34429_3	SARG|gi|447195836|ref|WP_001273092.1|	35.7	227	238	306	4.35e-40	139
k141_113301_3	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	29.8	208	295	346	4.79e-18	82.0
k141_113301_7	SARG|gb|AAK76137.1|ARO:3000024|patA	30.1	266	503	564	1.65e-29	120
k141_113301_8	SARG|gb|WP_104671188.1|ARO:3003948|efrA	55.1	247	267	575	1.26e-92	283
k141_113301_8	SARG|gb|AAK76137.1|ARO:3000024|patA	48.1	239	267	564	3.20e-72	230
k141_113301_8	SARG|gi|664042835|ref|WP_030582300.1|	46.3	246	267	604	1.78e-68	221
k141_113301_8	SARG|gi|695865802|ref|WP_032778631.1|	46.5	245	267	605	4.99e-68	220
k141_113301_8	SARG|gi|951183771|ref|WP_057661487.1|	46.1	245	267	603	6.73e-68	219
k141_113301_8	SARG|gi|764446018|ref|WP_044369325.1|	46.5	245	267	605	6.99e-68	219
k141_113301_8	SARG|gi|662129758|ref|WP_030081404.1|	46.3	246	267	605	6.99e-68	219
k141_113301_8	SARG|gi|664085850|ref|WP_030624018.1|	46.3	246	267	605	9.80e-68	219
k141_113301_8	SARG|gi|501350226|ref|WP_012381861.1|	46.3	246	267	603	1.32e-67	219
k141_113301_8	SARG|gi|827013130|ref|WP_047175495.1|	46.5	245	267	603	1.32e-67	219
k141_113301_9	SARG|gb|AAK76136.1|ARO:3000025|patB	35.9	577	619	588	2.95e-117	360
k141_113301_9	SARG|gb|CDO61516.1|ARO:3003949|efrB	51.5	326	619	362	1.77e-111	337
k141_113301_9	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.9	515	619	664	3.58e-103	326
k141_113301_9	SARG|gi|1045390184|ref|WP_065479071.1|	33.0	579	619	605	4.13e-94	300
k141_113301_9	SARG|gi|772774655|ref|WP_045322518.1|	32.3	600	619	620	9.02e-93	297
k141_113301_9	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	36.1	496	619	579	1.23e-92	296
k141_113301_9	SARG|gi|926356413|ref|WP_053687351.1|	32.0	600	619	620	3.48e-92	296
k141_113301_9	SARG|gi|926345639|ref|WP_053677539.1|	32.0	600	619	620	3.48e-92	296
k141_113301_9	SARG|gi|917127754|ref|WP_051734466.1|	31.8	600	619	620	3.48e-92	296
k141_113301_9	SARG|gi|799286378|ref|WP_045936958.1|	31.8	600	619	620	4.88e-92	295
k141_42426_1	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.6	269	476	467	1.08e-32	128
k141_42426_1	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.8	229	476	381	1.24e-30	121
k141_42426_1	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.8	229	476	381	1.24e-30	121
k141_42426_1	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.1	229	476	381	2.32e-30	120
k141_42426_1	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.1	229	476	381	2.32e-30	120
k141_42426_1	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.4	229	476	381	5.97e-30	119
k141_42426_1	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.4	229	476	381	5.97e-30	119
k141_42426_1	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.4	229	476	381	1.12e-29	118
k141_42426_1	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.4	229	476	381	1.12e-29	118
k141_42426_1	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.8	229	476	381	2.86e-29	117
k141_42426_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	49.3	227	235	228	5.40e-69	210
k141_42426_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.9	225	235	232	8.19e-59	184
k141_42426_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.9	226	235	231	1.59e-58	184
k141_42426_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.1	227	235	232	1.06e-56	179
k141_42426_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.1	227	235	232	1.06e-56	179
k141_42426_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	40.7	231	235	229	5.00e-54	172
k141_42426_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.0	223	235	219	1.05e-53	171
k141_42426_2	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.4	230	235	232	1.55e-53	171
k141_42426_2	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.4	230	235	232	2.19e-53	171
k141_42426_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	39.1	230	235	233	4.50e-53	170
k141_121764_4	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	24.9	269	361	397	8.50e-15	73.9
k141_10543_7	SARG|gb|CBL58195.1|ARO:3002831|vgaC	25.3	198	367	522	2.55e-06	48.1
k141_74337_16	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.3	120	266	232	2.73e-11	60.8
k141_74337_16	CARD|gb|AAG06465.1|ARO:3005063|cprR	30.8	130	266	223	1.00e-09	56.2
k141_74337_16	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.8	120	266	231	6.79e-09	53.9
k141_74337_16	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.1	106	266	219	9.35e-08	50.4
k141_74337_16	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.1	106	266	219	9.35e-08	50.4
k141_74337_16	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.1	106	266	220	9.43e-08	50.4
k141_74337_16	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.1	106	266	220	9.43e-08	50.4
k141_74337_16	CARD|gb|ATC67679.1|ARO:3000838|arlR	27.5	120	266	219	2.31e-07	49.3
k141_74337_16	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	25.6	117	266	228	2.49e-07	49.3
k141_74337_16	CARD|gb|AAD51348.1|ARO:3003066|smeR	29.4	126	266	229	3.70e-06	45.8
k141_26002_3	SARG|gi|974672242|ref|WP_059256507.1|	38.4	229	255	648	2.38e-35	132
k141_26002_3	SARG|gi|974641719|ref|WP_059227752.1|	38.4	229	255	648	2.38e-35	132
k141_26002_3	SARG|gi|446110299|ref|WP_000188154.1|	38.4	229	255	648	2.38e-35	132
k141_26002_3	SARG|ZP_02903696	38.4	229	255	648	2.38e-35	132
k141_26002_3	SARG|gi|974688082|ref|WP_059271287.1|	38.4	229	255	648	2.38e-35	132
k141_26002_3	SARG|gi|654658955|ref|WP_028119847.1|	35.9	237	255	648	8.34e-35	130
k141_26002_3	SARG|gi|1036100176|ref|WP_064669414.1|	35.4	237	255	648	4.00e-34	128
k141_26002_3	SARG|gi|895981299|ref|WP_049056431.1|	34.9	238	255	648	4.00e-34	128
k141_26002_3	SARG|gi|823281237|ref|WP_047037467.1|	34.9	238	255	648	4.00e-34	128
k141_26002_3	SARG|gi|895967513|ref|WP_049046752.1|	34.9	238	255	648	4.00e-34	128
k141_66262_12	SARG|gi|488374619|ref|WP_002444004.1|	25.9	429	454	452	3.09e-43	157
k141_66262_12	SARG|gi|505177635|ref|WP_015364737.1|	24.9	429	454	451	1.06e-40	150
k141_66262_12	SARG|ZP_04679156	24.7	429	454	451	3.71e-39	145
k141_66262_12	SARG|gi|686432388|ref|WP_031921070.1|	24.8	415	454	451	3.70e-34	132
k141_66262_12	SARG|gi|446573700|ref|WP_000651046.1|	24.6	415	454	451	5.08e-34	131
k141_66262_12	SARG|ZP_03986195	24.3	415	454	451	1.31e-33	130
k141_66262_12	SARG|gi|446573690|ref|WP_000651036.1|	23.8	421	454	451	1.80e-33	130
k141_66262_12	SARG|gi|516415429|ref|WP_017804827.1|	24.3	415	454	451	1.80e-33	130
k141_66262_12	SARG|gi|446573692|ref|WP_000651038.1|	24.2	434	454	451	1.80e-33	130
k141_66262_12	SARG|gi|446573695|ref|WP_000651041.1|	23.8	421	454	451	2.47e-33	129
k141_105897_5	SARG|gb|AVI44920.1|ARO:3004470|poxtA	25.6	203	478	542	1.56e-08	55.8
k141_105897_5	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	24.9	193	478	550	2.08e-08	55.5
k141_105897_5	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	25.5	200	478	544	3.61e-08	54.7
k141_105897_5	SARG|gb|APB03219.1|ARO:3003986|TaeA	18.6	226	478	648	6.36e-07	50.8
k141_105897_5	SARG|gb|QQA64075.1|ARO:3007043|msr(I)	25.6	223	478	485	2.94e-06	48.5
k141_105897_5	SARG|U82085.gene.p01	22.4	192	478	552	7.22e-06	47.4
k141_105897_5	ResF|poxtA-Ef_1_WP094899500.1_1	23.8	181	478	538	9.43e-06	47.0
k141_105897_5	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	23.8	181	478	543	9.47e-06	47.0
k141_105897_5	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	23.8	181	478	543	9.47e-06	47.0
k141_3035_1	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	31.5	146	195	481	1.04e-12	64.7
k141_3035_1	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	31.5	146	195	451	1.86e-12	63.9
k141_3036_3	CARD|gb|ADM92605.1|ARO:3000553|adeR	24.3	111	501	247	3.29e-08	53.5
k141_50277_4	SARG|gi|663330365|ref|WP_030329892.1|	34.6	393	590	607	6.78e-46	170
k141_50277_4	SARG|gi|944152509|ref|WP_055644808.1|	40.1	274	590	616	7.59e-46	170
k141_50277_4	SARG|gi|663155409|ref|WP_030194633.1|	34.4	393	590	605	1.69e-45	169
k141_50277_4	SARG|gi|664538723|ref|WP_031054357.1|	34.4	393	590	605	1.69e-45	169
k141_50277_4	SARG|gi|695865802|ref|WP_032778631.1|	33.6	393	590	605	4.34e-45	167
k141_50277_4	SARG|gi|662175949|ref|WP_030118884.1|	40.4	272	590	605	4.34e-45	167
k141_50277_4	SARG|gi|764446018|ref|WP_044369325.1|	33.8	393	590	605	8.11e-45	167
k141_50277_4	SARG|gi|664317010|ref|WP_030845774.1|	34.1	393	590	605	1.11e-44	166
k141_50277_4	SARG|gi|663286402|ref|WP_030292859.1|	34.1	393	590	605	1.11e-44	166
k141_50277_4	SARG|gi|663342223|ref|WP_030341347.1|	34.1	393	590	605	1.11e-44	166
k141_50277_5	SARG|gi|695842130|ref|WP_032755430.1|	28.4	522	565	603	1.89e-44	165
k141_50277_5	SARG|gi|928900436|ref|WP_053931243.1|	28.4	521	565	600	3.42e-44	164
k141_50277_5	SARG|gi|664579989|ref|WP_031094015.1|	28.4	521	565	601	3.46e-44	164
k141_50277_5	SARG|gi|490068471|ref|WP_003970646.1|	28.5	522	565	603	3.55e-44	164
k141_50277_5	SARG|gi|664170108|ref|WP_030704355.1|	28.5	513	565	603	4.85e-44	164
k141_50277_5	SARG|gi|664042835|ref|WP_030582300.1|	28.4	522	565	604	4.91e-44	164
k141_50277_5	SARG|gi|517787730|ref|WP_018957938.1|	28.5	522	565	610	5.27e-44	164
k141_50277_5	SARG|gi|501350226|ref|WP_012381861.1|	28.5	522	565	603	6.64e-44	164
k141_50277_5	SARG|gi|639148059|ref|WP_024490169.1|	35.3	312	565	602	8.97e-44	163
k141_50277_5	SARG|gi|505420018|ref|WP_015607120.1|	28.5	522	565	603	9.08e-44	163
k141_50277_8	SARG|L42544.gene.p01	30.4	628	887	651	1.48e-81	275
k141_50277_8	SARG|ZP_02952732	32.8	613	887	652	1.48e-80	272
k141_50277_8	SARG|ZP_02632674	32.8	613	887	660	1.76e-80	272
k141_50277_8	SARG|AAV80410	30.1	628	887	651	2.00e-80	272
k141_50277_8	SARG|L20800.gene.p01	32.8	613	887	652	2.83e-80	271
k141_50277_8	SARG|AJ514254.gene.p01	31.0	609	887	640	1.52e-79	269
k141_50277_8	SARG|YP_002850805	31.8	613	887	652	2.75e-79	269
k141_50277_8	SARG|NP_348076	31.0	613	887	652	5.11e-78	265
k141_50277_8	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	31.0	606	887	641	1.96e-76	261
k141_50277_8	SARG|AAZ79478	31.0	606	887	657	2.77e-76	261
k141_50277_15	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	28.9	242	534	361	4.15e-24	102
k141_50277_15	megares|MEG_7499|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.9	242	534	361	4.15e-24	102
k141_50277_15	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.9	239	534	354	6.89e-24	102
k141_50277_15	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.6	239	534	352	9.07e-24	101
k141_50277_15	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.6	239	534	376	1.25e-23	101
k141_50277_15	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	27.6	239	534	376	1.25e-23	101
k141_50277_15	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.0	239	534	354	1.71e-23	100
k141_50277_15	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.1	242	534	361	6.25e-23	99.4
k141_50277_15	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	28.1	242	534	361	6.25e-23	99.4
k141_50277_15	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.2	232	534	364	2.54e-20	91.7
k141_50277_16	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.2	126	485	231	1.84e-09	57.0
k141_113969_1	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.5	208	215	204	5.20e-25	96.3
k141_113969_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	28.6	192	215	219	9.49e-10	55.5
k141_113969_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	23.3	223	215	228	3.60e-09	53.9
k141_3318_1	SARG|gi|896190680|ref|WP_049199932.1|	23.5	361	399	563	3.05e-12	67.0
k141_3318_1	SARG|gi|1001786599|ref|WP_061324791.1|	24.2	363	399	563	5.39e-12	66.2
k141_3318_1	SARG|ZP_04612557	23.1	360	399	543	1.23e-11	65.1
k141_3318_1	SARG|YP_001477377	23.0	361	399	563	1.68e-11	64.7
k141_3318_1	SARG|ZP_04631861	23.3	361	399	543	3.85e-11	63.5
k141_3318_1	SARG|ZP_04635128	23.1	360	399	543	6.78e-11	62.8
k141_3318_1	SARG|gi|740410309|ref|WP_038243756.1|	23.8	361	399	563	6.95e-11	62.8
k141_3318_1	SARG|ZP_04615639	23.6	360	399	543	1.59e-10	61.6
k141_3318_1	SARG|AAS61092	23.2	358	399	563	1.63e-10	61.6
k141_3318_1	SARG|YP_001007250	22.7	361	399	563	2.16e-10	61.2
k141_3318_3	CARD|gb|AAC75429.1|ARO:3000833|evgS	31.9	376	658	1197	3.71e-46	175
k141_3318_3	CARD|gb|AEX49906.1|ARO:3003583|basS	27.1	247	658	477	4.16e-12	67.8
k141_18359_15	SARG|gi|313614636|gb|EFR88215.1|	31.1	428	441	453	1.88e-68	223
k141_18359_15	SARG|gi|313638554|gb|EFS03703.1|	30.3	422	441	453	5.58e-67	219
k141_18359_15	SARG|gi|505177635|ref|WP_015364737.1|	30.8	435	441	451	4.34e-65	214
k141_18359_15	SARG|ZP_04679156	30.8	435	441	451	8.53e-65	214
k141_18359_15	SARG|gi|488374619|ref|WP_002444004.1|	29.5	427	441	452	1.31e-63	211
k141_18359_15	SARG|gi|446573715|ref|WP_000651061.1|	29.3	427	441	451	2.13e-60	202
k141_18359_15	SARG|gi|686408548|ref|WP_031913080.1|	29.3	427	441	451	4.18e-60	201
k141_18359_15	SARG|gi|686123390|ref|WP_031769354.1|	29.3	427	441	451	4.18e-60	201
k141_18359_15	SARG|gi|686432388|ref|WP_031921070.1|	29.3	427	441	451	4.18e-60	201
k141_18359_15	SARG|ZP_03986195	29.3	427	441	451	4.18e-60	201
k141_18359_33	CARD|gb|ADM92605.1|ARO:3000553|adeR	33.9	121	869	247	6.32e-13	68.6
k141_18359_33	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.4	115	869	231	6.62e-13	68.2
k141_18359_33	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	34.7	124	869	252	6.81e-13	68.6
k141_18359_33	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	30.4	115	869	232	1.83e-11	63.9
k141_18359_33	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	26.8	123	869	231	1.59e-09	58.2
k141_18359_33	CARD|gb|AAD51348.1|ARO:3003066|smeR	28.7	122	869	229	1.79e-07	52.0
k141_35362_8	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	21.1	294	438	370	5.28e-08	53.5
k141_35362_8	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.9	116	438	365	1.18e-06	49.3
k141_35362_8	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.3	222	438	381	1.23e-06	49.3
k141_35362_8	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.3	222	438	381	1.23e-06	49.3
k141_35362_8	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.6	154	438	381	8.85e-06	46.6
k141_35362_8	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.6	154	438	381	8.85e-06	46.6
k141_35362_9	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.9	232	239	231	9.95e-61	189
k141_35362_9	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.5	232	239	231	1.41e-60	189
k141_35362_9	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	41.1	231	239	231	4.00e-60	188
k141_35362_9	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.1	231	239	231	4.00e-60	188
k141_35362_9	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.1	232	239	231	1.60e-59	186
k141_35362_9	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.4	230	239	232	6.64e-59	185
k141_35362_9	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.4	230	239	232	6.64e-59	185
k141_35362_9	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.5	234	239	231	2.08e-57	181
k141_35362_9	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	37.6	234	239	239	2.64e-57	181
k141_35362_9	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.1	232	239	235	4.69e-57	180
k141_35362_16	SARG|gi|974588181|ref|WP_059178476.1|	41.8	220	234	646	1.93e-52	178
k141_35362_16	SARG|YP_001176128	41.4	220	234	646	5.18e-52	177
k141_35362_16	SARG|gi|895872463|ref|WP_048979698.1|	41.4	220	234	646	1.93e-51	175
k141_35362_16	SARG|gi|746243059|ref|WP_039291473.1|	38.6	236	234	648	1.97e-51	175
k141_35362_16	SARG|gi|556487375|ref|WP_023335108.1|	41.8	220	234	646	2.68e-51	175
k141_35362_16	SARG|gi|695731723|ref|WP_032658224.1|	41.4	220	234	646	3.72e-51	174
k141_35362_16	SARG|gi|835749851|ref|WP_047648187.1|	41.4	220	234	646	3.72e-51	174
k141_35362_16	SARG|gi|697052471|ref|WP_033145077.1|	41.4	220	234	646	3.72e-51	174
k141_35362_16	SARG|gi|695722592|ref|WP_032649220.1|	41.4	220	234	646	3.72e-51	174
k141_35362_16	SARG|gi|895868403|ref|WP_048976842.1|	41.4	220	234	646	3.72e-51	174
k141_35362_18	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	27.4	698	681	641	1.25e-41	159
k141_35362_19	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	49.0	249	258	255	1.05e-83	249
k141_35362_19	SARG|gi|922960663|ref|WP_053388845.1|	39.8	221	258	648	1.65e-53	182
k141_35362_19	SARG|gi|757799695|ref|WP_043016897.1|	39.8	221	258	648	2.30e-53	181
k141_35362_19	SARG|gi|1045891604|ref|WP_065554100.1|	39.8	221	258	648	2.30e-53	181
k141_35362_19	SARG|gi|507082903|ref|WP_016153652.1|	39.8	221	258	648	2.30e-53	181
k141_35362_19	SARG|gi|740856590|ref|WP_038641842.1|	39.8	221	258	648	2.30e-53	181
k141_35362_19	SARG|gi|502669352|ref|WP_012905216.1|	40.3	221	258	648	2.30e-53	181
k141_35362_19	SARG|gi|507086196|ref|WP_016156937.1|	39.8	221	258	648	2.30e-53	181
k141_35362_19	SARG|gi|835233765|ref|WP_047410073.1|	39.8	221	258	648	4.44e-53	181
k141_35362_19	SARG|gi|754951242|ref|WP_042307417.1|	39.8	221	258	648	4.44e-53	181
k141_35362_20	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	43.4	235	347	341	1.47e-53	178
k141_35362_21	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	52.5	221	224	223	4.33e-79	235
k141_35362_21	CARD|gb|ATC67679.1|ARO:3000838|arlR	32.4	222	224	219	6.04e-38	130
k141_35362_21	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.8	221	224	219	1.39e-32	116
k141_35362_21	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.8	221	224	219	1.96e-32	116
k141_35362_21	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.8	221	224	220	2.01e-32	116
k141_35362_21	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.8	221	224	220	2.83e-32	115
k141_35362_21	CARD|gb|ADM92605.1|ARO:3000553|adeR	30.2	225	224	247	1.62e-30	112
k141_35362_21	CARD|gb|AAD51348.1|ARO:3003066|smeR	32.0	219	224	229	6.78e-28	104
k141_35362_21	SARG|ZP_02848503	29.4	221	224	221	7.93e-28	104
k141_35362_21	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	27.9	226	224	231	3.86e-27	102
k141_35362_25	SARG|gi|686309068|ref|WP_031870147.1|	29.0	424	463	451	1.85e-42	155
k141_35362_25	SARG|gi|446573695|ref|WP_000651041.1|	28.5	424	463	451	3.54e-42	154
k141_35362_25	SARG|gi|537465183|ref|WP_020976941.1|	28.5	424	463	451	4.90e-42	154
k141_35362_25	SARG|gi|686396521|ref|WP_031908504.1|	28.8	424	463	451	4.90e-42	154
k141_35362_25	SARG|gi|565830932|ref|WP_023914633.1|	28.5	424	463	451	6.78e-42	153
k141_35362_25	SARG|gi|686408548|ref|WP_031913080.1|	28.5	424	463	451	6.78e-42	153
k141_35362_25	SARG|ZP_03986195	28.5	424	463	451	6.78e-42	153
k141_35362_25	SARG|gi|446573715|ref|WP_000651061.1|	29.0	424	463	451	6.78e-42	153
k141_35362_25	SARG|gi|686113687|ref|WP_031764317.1|	28.8	424	463	451	6.78e-42	153
k141_35362_25	SARG|gi|686367913|ref|WP_031894914.1|	28.8	424	463	451	6.78e-42	153
k141_122696_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	26.1	180	249	362	1.02e-14	71.6
k141_122696_2	SARG|YP_001176128	29.1	244	237	646	5.14e-22	93.2
k141_122696_2	SARG|gi|749017716|ref|WP_040076354.1|	29.3	232	237	646	9.46e-22	92.4
k141_122696_2	SARG|gi|968563772|ref|WP_058587854.1|	27.6	239	237	648	1.29e-21	92.0
k141_122696_2	SARG|gi|763407609|ref|WP_044264203.1|	27.6	239	237	648	1.29e-21	92.0
k141_122696_2	SARG|gi|974588181|ref|WP_059178476.1|	28.3	244	237	646	1.74e-21	91.7
k141_122696_2	SARG|gi|757782629|ref|WP_043001213.1|	27.6	239	237	648	2.37e-21	91.3
k141_122696_2	SARG|gi|992390012|ref|WP_061077002.1|	27.6	239	237	648	2.37e-21	91.3
k141_122696_2	SARG|gi|764278838|ref|WP_044327089.1|	27.6	239	237	648	3.21e-21	90.9
k141_122696_2	SARG|gi|817104523|ref|WP_046477871.1|	27.6	239	237	648	5.90e-21	90.1
k141_122696_2	SARG|gi|754927849|ref|WP_042284850.1|	28.4	225	237	648	1.99e-20	88.6
k141_122696_11	SARG|gb|AAC75089.1|ARO:3003577|ugd	60.0	412	494	388	3.13e-168	479
k141_58599_6	SARG|gb|AML99881.1|ARO:3001327|mdtK	27.7	440	455	474	3.43e-44	160
k141_3788_2	CARD|gb|AEX49906.1|ARO:3003583|basS	26.5	253	424	477	3.22e-14	73.2
k141_3788_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.8	125	424	232	6.24e-13	67.0
k141_3788_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.7	113	424	231	5.08e-12	64.3
k141_3788_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	29.6	115	424	228	4.81e-09	55.5
k141_3788_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	28.3	113	424	219	7.87e-09	54.7
k141_3788_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.7	114	424	219	1.55e-07	50.8
k141_3788_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.7	114	424	219	1.55e-07	50.8
k141_3788_2	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.7	114	424	220	1.57e-07	50.8
k141_3788_2	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.7	114	424	220	2.11e-07	50.4
k141_3788_2	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.5	108	424	220	4.08e-06	46.6
k141_18652_1	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	33.2	370	390	366	9.46e-57	189
k141_18652_1	SARG|gi|498467693|ref|WP_010773049.1|	33.7	368	390	700	2.16e-51	181
k141_18652_1	SARG|gb|ABA71733.1|ARO:3002972|vanTG	34.5	345	390	712	8.31e-50	177
k141_18652_1	SARG|FJ872411.1.gene43.p01	32.3	368	390	702	1.04e-49	177
k141_18652_1	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	31.1	383	390	712	1.37e-47	171
k141_18652_1	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	30.7	345	390	711	4.62e-36	138
k141_18652_6	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	38.2	228	254	255	4.03e-40	138
k141_18652_6	SARG|gi|803568669|ref|WP_046077412.1|	38.5	234	254	648	5.74e-38	139
k141_18652_6	SARG|gi|446110352|ref|WP_000188207.1|	38.5	234	254	648	5.74e-38	139
k141_18652_6	SARG|YP_002382193	38.5	234	254	648	5.74e-38	139
k141_18652_6	SARG|gi|803575554|ref|WP_046081557.1|	38.5	234	254	648	5.74e-38	139
k141_18652_6	SARG|gi|446110351|ref|WP_000188206.1|	38.5	234	254	648	5.74e-38	139
k141_18652_6	SARG|gi|502669352|ref|WP_012905216.1|	36.0	239	254	648	2.31e-35	132
k141_18652_6	SARG|gi|1035706844|ref|WP_064548272.1|	37.2	234	254	648	1.52e-34	129
k141_18652_6	SARG|gi|1035717981|ref|WP_064557480.1|	36.3	234	254	648	2.08e-34	129
k141_18652_6	SARG|gi|736472622|ref|WP_034494292.1|	36.3	234	254	648	2.84e-34	129
k141_106537_1	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	25.4	366	490	633	2.44e-24	105
k141_106537_1	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	26.3	365	490	674	6.44e-14	73.2
k141_106537_1	SARG|gb|BAI83385.1|ARO:3003440|mecB	26.3	365	490	674	8.52e-14	72.8
k141_106537_1	SARG|gb|AQX82857.1|ARO:3004185|mecD	24.5	351	490	678	7.54e-12	66.6
k141_83015_12	CARD|gb|AAG06465.1|ARO:3005063|cprR	27.5	109	362	223	7.03e-08	51.6
k141_83015_22	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.1	113	120	228	1.80e-13	63.2
k141_83015_22	CARD|gb|BAB36671.1|ARO:3000832|evgA	30.0	110	120	204	1.89e-12	60.1
k141_83015_22	CARD|gb|AAD51348.1|ARO:3003066|smeR	27.4	117	120	229	1.76e-10	55.1
k141_83015_22	CARD|gb|AAC73788.1|ARO:3003841|kdpE	28.6	105	120	225	3.26e-10	54.3
k141_83015_22	CARD|gb|ATC67679.1|ARO:3000838|arlR	25.4	118	120	219	1.14e-09	52.8
k141_83015_22	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	28.4	102	120	225	1.19e-09	52.8
k141_83015_22	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.7	101	120	1197	4.09e-07	46.2
k141_91810_3	SARG|gi|926400371|ref|WP_053728483.1|	28.7	534	589	603	4.04e-40	153
k141_91810_3	SARG|gi|739906046|ref|WP_037756452.1|	27.5	530	589	620	1.37e-38	149
k141_91810_3	SARG|gi|516574297|ref|WP_017949361.1|	27.6	529	589	620	1.86e-38	149
k141_91810_3	SARG|gi|664556405|ref|WP_031071225.1|	28.3	533	589	602	2.14e-38	148
k141_91810_3	SARG|gi|944152509|ref|WP_055644808.1|	28.2	528	589	616	2.43e-38	148
k141_91810_3	SARG|gi|493394434|ref|WP_006350564.1|	28.3	526	589	602	5.33e-38	147
k141_91810_3	SARG|gi|817122037|ref|WP_046494699.1|	27.8	526	589	613	3.63e-37	145
k141_91810_3	SARG|gi|917229923|ref|WP_051836635.1|	27.0	529	589	620	3.85e-37	145
k141_91810_3	SARG|gi|944009777|ref|WP_055601444.1|	27.6	543	589	628	7.50e-37	144
k141_91810_3	SARG|gi|517347347|ref|WP_018522839.1|	28.1	526	589	601	2.01e-36	142
k141_26709_3	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.1	309	790	381	3.45e-25	107
k141_26709_3	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.1	309	790	381	3.45e-25	107
k141_26709_3	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.8	309	790	381	4.65e-25	107
k141_26709_3	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.8	309	790	381	4.65e-25	107
k141_26709_3	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	29.7	229	790	365	2.84e-20	92.4
k141_26709_3	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.8	233	790	370	1.31e-19	90.5
k141_26709_3	CARD|gb|ACM47284.1|ARO:3002934|vanS_in_vanD_cl	30.4	148	790	233	2.65e-09	57.4
k141_26709_3	megares|MEG_7508|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.4	148	790	233	2.65e-09	57.4
k141_26709_3	megares|MEG_7510|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.4	148	790	233	3.56e-09	57.0
k141_26709_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	48.1	231	236	232	7.86e-80	238
k141_26709_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	48.1	231	236	232	7.86e-80	238
k141_26709_4	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	47.0	230	236	231	6.65e-76	228
k141_26709_4	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	47.0	230	236	231	6.65e-76	228
k141_26709_4	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	47.2	231	236	235	1.07e-75	228
k141_26709_4	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	48.3	230	236	233	2.02e-75	227
k141_26709_4	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	48.3	234	236	239	1.99e-74	224
k141_26709_4	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	46.5	230	236	231	3.55e-73	221
k141_26709_4	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.8	230	236	231	3.30e-71	216
k141_26709_4	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.8	230	236	231	4.68e-71	216
k141_11840_5	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	29.8	248	802	357	5.04e-27	112
k141_11840_5	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	29.8	248	802	357	5.04e-27	112
k141_11840_5	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.6	241	802	381	7.28e-23	100
k141_11840_5	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.6	241	802	381	7.28e-23	100
k141_11840_5	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.9	275	802	365	1.43e-22	99.4
k141_11840_5	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.8	225	802	381	1.76e-22	99.4
k141_11840_5	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.2	225	802	381	1.76e-22	99.4
k141_11840_5	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.8	225	802	381	1.76e-22	99.4
k141_11840_5	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.2	225	802	381	1.76e-22	99.4
k141_11840_5	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.0	232	802	382	2.40e-22	99.0
k141_11840_6	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	46.9	228	232	231	2.67e-74	224
k141_11840_6	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	46.9	228	232	231	2.67e-74	224
k141_11840_6	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	48.0	229	232	232	5.54e-74	223
k141_11840_6	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	48.0	229	232	232	5.54e-74	223
k141_11840_6	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	45.9	233	232	239	3.69e-71	216
k141_11840_6	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.2	228	232	231	5.74e-71	215
k141_11840_6	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.3	228	232	231	9.34e-70	212
k141_11840_6	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.3	228	232	231	1.88e-69	211
k141_11840_6	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	43.0	230	232	233	6.52e-68	207
k141_11840_6	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	44.4	232	232	235	7.95e-67	205
k141_11840_9	SARG|gi|488374619|ref|WP_002444004.1|	22.5	369	468	452	1.65e-17	83.6
k141_11890_1	SARG|P42332	39.9	223	318	306	5.59e-49	164
k141_11890_1	SARG|ZP_04081918	42.5	212	318	306	5.59e-49	164
k141_11890_1	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	39.9	223	318	306	5.59e-49	164
k141_11890_1	SARG|gi|510143239|gb|AGN36970.1|	39.9	223	318	313	6.69e-49	164
k141_11890_1	SARG|ABB80128	39.9	223	318	306	7.86e-49	164
k141_11890_1	SARG|AAD21213	39.9	223	318	306	2.19e-48	163
k141_11890_1	SARG|gi|500194536|ref|WP_011867743.1|	39.0	223	318	306	4.32e-48	162
k141_11890_1	SARG|gi|447195835|ref|WP_001273091.1|	42.0	212	318	306	6.08e-48	162
k141_11890_1	SARG|gi|447195836|ref|WP_001273092.1|	41.5	212	318	306	1.69e-47	160
k141_11890_1	SARG|gi|500448961|gb|EOP61695.1|	40.1	212	318	306	3.62e-46	157
k141_92148_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	44.0	225	234	225	4.66e-64	197
k141_92148_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	44.0	225	234	225	4.66e-64	197
k141_92148_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.4	228	234	231	3.35e-43	144
k141_92148_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	35.1	228	234	232	4.27e-41	139
k141_92148_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.4	222	234	219	8.42e-41	138
k141_92148_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	35.1	228	234	235	3.65e-40	137
k141_92148_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	34.2	225	234	233	6.87e-40	136
k141_92148_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	31.5	222	234	229	8.71e-40	135
k141_92148_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.7	223	234	231	1.30e-39	135
k141_92148_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	32.7	226	234	232	1.33e-39	135
k141_51198_11	SARG|gb|AAV85982.1|ARO:3000535|macB	30.9	447	443	644	8.19e-42	155
k141_51198_11	SARG|gi|494938585|ref|WP_007664615.1|	28.0	450	443	647	3.35e-35	137
k141_51198_11	SARG|gi|495067432|ref|WP_007792257.1|	27.6	450	443	647	1.14e-34	135
k141_51198_11	SARG|YP_001438541	27.3	450	443	647	1.55e-34	135
k141_51198_11	SARG|gi|938460528|ref|WP_054624864.1|	27.3	450	443	647	1.55e-34	135
k141_51198_11	SARG|gi|490522515|ref|WP_004387938.1|	27.3	450	443	647	1.55e-34	135
k141_51198_11	SARG|gi|696420214|ref|WP_032990021.1|	27.3	450	443	647	1.55e-34	135
k141_51198_11	SARG|gi|696423952|ref|WP_032993748.1|	27.6	450	443	647	1.55e-34	135
k141_51198_11	SARG|gi|506220920|ref|WP_015740695.1|	27.1	447	443	647	2.10e-34	134
k141_51198_11	SARG|gi|1020141879|ref|WP_063264839.1|	27.3	450	443	647	2.10e-34	134
k141_51198_12	SARG|gi|803568669|ref|WP_046077412.1|	46.0	224	234	648	1.57e-63	207
k141_51198_12	SARG|gi|446110352|ref|WP_000188207.1|	46.0	224	234	648	1.57e-63	207
k141_51198_12	SARG|YP_002382193	46.0	224	234	648	1.57e-63	207
k141_51198_12	SARG|gi|803575554|ref|WP_046081557.1|	46.0	224	234	648	1.57e-63	207
k141_51198_12	SARG|gi|446110351|ref|WP_000188206.1|	46.0	224	234	648	1.57e-63	207
k141_51198_12	SARG|gi|992390012|ref|WP_061077002.1|	45.2	221	234	648	1.17e-62	205
k141_51198_12	SARG|gi|754927849|ref|WP_042284850.1|	44.8	221	234	648	2.28e-62	204
k141_51198_12	SARG|gi|985815823|ref|WP_060876116.1|	45.1	224	234	646	3.08e-62	204
k141_51198_12	SARG|gi|749017716|ref|WP_040076354.1|	45.8	216	234	646	3.08e-62	204
k141_51198_12	SARG|gi|757782629|ref|WP_043001213.1|	44.8	221	234	648	3.18e-62	204
k141_43976_3	SARG|gi|924503108|ref|WP_053510027.1|	31.9	279	478	648	9.21e-31	124
k141_43976_3	SARG|gi|495736522|ref|WP_008461101.1|	30.3	307	478	648	1.24e-30	124
k141_43976_3	SARG|gi|746243059|ref|WP_039291473.1|	30.3	307	478	648	1.24e-30	124
k141_43976_3	SARG|gi|746253210|ref|WP_039301529.1|	30.3	307	478	648	1.24e-30	124
k141_43976_3	SARG|YP_002044935	31.9	279	478	648	2.25e-30	123
k141_43976_3	SARG|gi|736472622|ref|WP_034494292.1|	30.6	307	478	648	2.25e-30	123
k141_43976_3	SARG|gi|495067432|ref|WP_007792257.1|	31.5	279	478	647	4.07e-30	122
k141_43976_3	SARG|gi|554689873|ref|WP_023186409.1|	32.1	280	478	648	4.08e-30	122
k141_43976_3	SARG|gi|555268037|ref|WP_023249477.1|	31.5	279	478	648	4.08e-30	122
k141_43976_3	SARG|gi|446048048|ref|WP_000125903.1|	31.9	279	478	648	4.08e-30	122
k141_43976_5	SARG|gb|AAV85982.1|ARO:3000535|macB	46.3	218	246	644	1.97e-66	216
k141_43976_5	SARG|gi|504542119|ref|WP_014729221.1|	46.6	223	246	647	2.17e-65	213
k141_43976_5	SARG|YP_001438541	46.2	223	246	647	1.16e-64	211
k141_43976_5	SARG|gi|938461734|ref|WP_054625806.1|	46.2	223	246	647	1.16e-64	211
k141_43976_5	SARG|gi|938460528|ref|WP_054624864.1|	46.2	223	246	647	1.16e-64	211
k141_43976_5	SARG|gi|490522515|ref|WP_004387938.1|	46.2	223	246	647	1.16e-64	211
k141_43976_5	SARG|gi|1020141879|ref|WP_063264839.1|	46.2	223	246	647	1.62e-64	211
k141_43976_5	SARG|gi|742384718|ref|WP_038863845.1|	47.1	223	246	647	2.27e-64	210
k141_43976_5	SARG|gi|495004199|ref|WP_007730213.1|	47.1	223	246	647	3.17e-64	210
k141_43976_5	SARG|gi|742409107|ref|WP_038888226.1|	47.1	223	246	647	3.17e-64	210
k141_59278_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	22.4	833	806	1024	2.01e-32	134
k141_59278_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.4	833	806	1024	2.01e-32	134
k141_59278_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.4	833	806	1024	2.01e-32	134
k141_59278_1	SARG|gb|CAA53189|ARO:3000521|mupA	22.4	833	806	1024	2.01e-32	134
k141_59278_1	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	22.7	929	806	1033	1.89e-31	131
k141_59278_1	SARG|gb|AEY83581|ARO:3000510|mupB	22.6	921	806	1033	2.49e-31	130
k141_59278_1	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	20.6	926	806	1107	1.27e-13	73.9
k141_59278_1	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	20.6	926	806	1107	1.27e-13	73.9
k141_114955_9	SARG|gi|851899656|ref|WP_048211088.1|	20.5	342	314	660	3.52e-13	68.9
k141_114955_9	SARG|gi|391316952|gb|EIQ74337.1|	20.8	342	314	660	4.72e-13	68.6
k141_114955_9	SARG|gi|696375142|ref|WP_032949690.1|	21.3	342	314	660	4.72e-13	68.6
k141_114955_9	SARG|gi|851935911|ref|WP_048224705.1|	21.3	342	314	660	6.32e-13	68.2
k141_114955_9	SARG|gi|851965596|ref|WP_048234849.1|	21.3	342	314	660	6.32e-13	68.2
k141_114955_9	SARG|gi|696369048|ref|WP_032944060.1|	21.3	342	314	660	6.32e-13	68.2
k141_114955_9	SARG|gi|489931383|ref|WP_003834702.1|	21.3	342	314	660	6.32e-13	68.2
k141_114955_9	SARG|ZP_02901868	21.6	342	314	660	6.32e-13	68.2
k141_114955_9	SARG|gi|446782981|ref|WP_000860237.1|	21.9	342	314	660	1.13e-12	67.4
k141_114955_9	SARG|YP_002850217	21.1	342	314	660	1.13e-12	67.4
k141_67830_6	SARG|gi|497748188|ref|WP_010062372.1|	45.0	149	161	605	1.13e-41	145
k141_67830_6	SARG|gi|1011969930|ref|WP_062776015.1|	44.4	153	161	601	1.52e-41	145
k141_67830_6	SARG|gi|943896259|ref|WP_055534530.1|	44.4	153	161	601	2.10e-41	144
k141_67830_6	SARG|gi|944470764|ref|WP_055701183.1|	44.4	153	161	601	2.90e-41	144
k141_67830_6	SARG|gi|943909899|ref|WP_055545300.1|	44.4	153	161	601	5.55e-41	143
k141_67830_6	SARG|gi|951183771|ref|WP_057661487.1|	45.0	149	161	603	7.81e-41	143
k141_67830_6	SARG|gi|1045390184|ref|WP_065479071.1|	45.0	149	161	605	7.93e-41	143
k141_67830_6	SARG|gi|860594225|ref|WP_048475168.1|	44.2	154	161	620	8.88e-41	143
k141_67830_6	SARG|gi|664244930|ref|WP_030776974.1|	43.8	153	161	601	1.47e-40	142
k141_67830_6	SARG|gi|517347347|ref|WP_018522839.1|	44.4	153	161	601	1.47e-40	142
k141_114978_7	SARG|gb|ADZ12699.1|ARO:3005091|RanA	22.8	237	267	258	9.94e-18	79.3
k141_114978_7	SARG|gi|803568669|ref|WP_046077412.1|	31.1	206	267	648	5.49e-17	79.3
k141_114978_7	SARG|gi|446110352|ref|WP_000188207.1|	31.1	206	267	648	5.49e-17	79.3
k141_114978_7	SARG|YP_002382193	31.1	206	267	648	5.49e-17	79.3
k141_114978_7	SARG|gi|803575554|ref|WP_046081557.1|	31.1	206	267	648	5.49e-17	79.3
k141_114978_7	SARG|gi|446110351|ref|WP_000188206.1|	31.1	206	267	648	5.49e-17	79.3
k141_114978_7	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	29.6	189	267	293	2.72e-16	75.9
k141_114978_7	SARG|gi|1035670474|ref|WP_064517458.1|	29.3	215	267	648	3.32e-16	77.0
k141_114978_7	SARG|gi|1035717981|ref|WP_064557480.1|	29.3	215	267	648	3.32e-16	77.0
k141_114978_7	SARG|gi|502669352|ref|WP_012905216.1|	29.5	210	267	648	4.48e-16	76.6
k141_114978_19	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	45.1	688	641	703	2.10e-179	525
k141_44224_4	SARG|gb|APB03216.1|ARO:3003982|LlmA	62.9	286	286	287	6.07e-141	397
k141_19196_8	CARD|gb|ADM92605.1|ARO:3000553|adeR	29.4	109	553	247	4.78e-09	56.2
k141_19196_8	CARD|gb|ATC67679.1|ARO:3000838|arlR	25.7	109	553	219	5.78e-06	46.6
k141_19196_11	SARG|ZP_04081918	28.9	228	503	306	5.42e-15	74.7
k141_19196_11	SARG|gi|447195835|ref|WP_001273091.1|	28.5	228	503	306	9.80e-15	73.9
k141_19196_11	SARG|gi|447195836|ref|WP_001273092.1|	28.5	228	503	306	9.80e-15	73.9
k141_19196_11	SARG|gi|445996719|ref|WP_000074574.1|	27.6	232	503	309	2.45e-14	72.8
k141_19196_11	SARG|gi|542061059|gb|ERI11611.1|	29.7	229	503	316	2.63e-14	72.8
k141_19196_11	SARG|gi|445996722|ref|WP_000074577.1|	27.6	232	503	309	3.29e-14	72.4
k141_19196_11	SARG|gi|447057509|ref|WP_001134765.1|	26.8	231	503	309	4.42e-14	72.0
k141_19196_11	SARG|gi|445996723|ref|WP_000074578.1|	27.6	232	503	309	4.42e-14	72.0
k141_19196_11	SARG|gi|445996724|ref|WP_000074579.1|	27.2	232	503	309	7.97e-14	71.2
k141_19196_11	SARG|gi|884875933|emb|CKG93789.1|	27.2	232	503	309	7.97e-14	71.2
k141_19196_15	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.5	228	221	232	2.17e-37	129
k141_19196_15	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.5	228	221	232	2.17e-37	129
k141_19196_15	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.1	225	221	231	6.54e-36	125
k141_19196_15	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	35.8	226	221	231	9.22e-36	125
k141_19196_15	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.8	226	221	231	9.22e-36	125
k141_19196_15	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	34.0	238	221	239	1.59e-35	124
k141_19196_15	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	34.2	225	221	232	7.39e-35	122
k141_19196_15	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	33.3	234	221	232	2.91e-34	121
k141_19196_15	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	34.2	225	221	232	4.09e-34	120
k141_19196_15	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	34.2	225	221	232	5.76e-34	120
k141_99485_1	CARD|gb|AAC75429.1|ARO:3000833|evgS	34.7	245	800	1197	2.56e-30	127
k141_99485_1	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.7	249	800	381	9.28e-16	79.0
k141_99485_1	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.7	249	800	381	9.28e-16	79.0
k141_99485_1	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	24.5	237	800	380	6.93e-15	76.3
k141_99485_1	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.5	237	800	380	6.93e-15	76.3
k141_99485_1	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.3	241	800	381	6.99e-15	76.3
k141_99485_1	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.3	241	800	381	6.99e-15	76.3
k141_99485_1	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.6	242	800	381	1.24e-14	75.5
k141_99485_1	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.6	242	800	381	1.24e-14	75.5
k141_99485_1	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.2	242	800	381	1.66e-14	75.1
k141_107405_4	SARG|gi|740610794|ref|WP_038396317.1|	40.4	225	254	648	7.21e-37	136
k141_107405_4	SARG|YP_001571041	40.0	225	254	648	2.55e-36	134
k141_107405_4	SARG|gi|960873409|ref|WP_058345546.1|	40.0	225	254	648	2.55e-36	134
k141_107405_4	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	36.2	224	254	255	8.69e-35	124
k141_107405_4	SARG|gb|AAV85982.1|ARO:3000535|macB	41.2	204	254	644	7.16e-34	127
k141_107405_4	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	31.4	223	254	579	7.03e-20	87.4
k141_107405_4	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	31.4	229	254	579	5.87e-19	84.7
k141_107405_9	SARG|YP_001176128	34.4	224	575	646	1.16e-24	107
k141_107405_9	SARG|gi|974588181|ref|WP_059178476.1|	33.9	224	575	646	2.73e-24	106
k141_107405_9	SARG|gi|749017716|ref|WP_040076354.1|	34.4	224	575	646	2.73e-24	106
k141_107405_9	SARG|gi|976150171|ref|WP_059308384.1|	34.8	224	575	646	3.63e-24	105
k141_107405_9	SARG|gi|502669352|ref|WP_012905216.1|	32.4	222	575	648	1.47e-22	100
k141_107405_9	SARG|gi|817104523|ref|WP_046477871.1|	32.0	222	575	648	3.32e-21	96.7
k141_107405_9	SARG|gi|754964360|ref|WP_042320280.1|	32.0	222	575	648	3.32e-21	96.7
k141_107405_9	SARG|gi|754927849|ref|WP_042284850.1|	31.5	222	575	648	3.32e-21	96.7
k141_107405_9	SARG|gi|764278838|ref|WP_044327089.1|	32.0	222	575	648	3.32e-21	96.7
k141_107405_9	SARG|gi|757782629|ref|WP_043001213.1|	31.5	222	575	648	4.40e-21	96.3
k141_107405_19	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	43.2	132	164	166	6.62e-29	103
k141_107405_19	NCBI|WP_038694170.1|1|1|dfrA49|dfrA49|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA49|AMR|diaminopyrimidine	41.1	141	164	167	1.92e-28	102
k141_107405_19	SARG|CAE53424	39.1	133	164	169	4.40e-24	91.3
k141_107405_19	SARG|gb|ASF80997.1|ARO:3005164|dfrA35	35.7	143	164	170	6.00e-21	83.2
k141_107405_19	SARG|gb|AAK64581.1|ARO:3004568|dfrA18	34.8	161	164	184	1.76e-10	55.8
k141_107405_19	SARG|gb|CAB06660.1|ARO:3004644|dfrA6	29.2	130	164	157	2.25e-10	55.1
k141_107405_19	SARG|gb|ACY06082.1|ARO:3004547|dfrA6	26.5	132	164	157	6.06e-10	53.9
k141_107405_19	SARG|gb|BAD88719.1|ARO:3005084|dfrA31	25.8	132	164	157	8.42e-10	53.5
k141_5136_3	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.4	519	547	655	7.11e-75	249
k141_5136_3	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.4	519	547	655	9.92e-75	248
k141_5136_3	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	519	547	655	9.92e-75	248
k141_5136_3	SARG|gb|AKA86814|ARO:3003746|optrA	32.2	519	547	655	9.92e-75	248
k141_5136_3	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.8	519	547	655	1.38e-74	248
k141_5136_3	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	519	547	655	2.69e-74	247
k141_5136_3	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	519	547	655	2.69e-74	247
k141_5136_3	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	519	547	655	2.69e-74	247
k141_5136_3	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	519	547	655	2.69e-74	247
k141_5136_3	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	519	547	655	5.24e-74	246
k141_60057_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	34.2	480	506	575	4.07e-87	278
k141_60057_1	SARG|gb|AAK76137.1|ARO:3000024|patA	32.7	459	506	564	6.13e-77	251
k141_60057_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	34.9	307	506	362	8.04e-54	184
k141_60057_1	SARG|gi|1045390184|ref|WP_065479071.1|	29.5	482	506	605	7.78e-52	184
k141_60057_1	SARG|gi|695842130|ref|WP_032755430.1|	29.9	481	506	603	1.38e-50	181
k141_60057_1	SARG|gi|944470764|ref|WP_055701183.1|	29.7	478	506	601	6.72e-50	179
k141_60057_1	SARG|gi|943909899|ref|WP_055545300.1|	29.8	480	506	601	6.72e-50	179
k141_60057_1	SARG|gi|501350226|ref|WP_012381861.1|	28.9	481	506	603	1.32e-49	178
k141_60057_1	SARG|gi|928900436|ref|WP_053931243.1|	29.8	480	506	600	1.74e-49	178
k141_60057_1	SARG|gi|664579989|ref|WP_031094015.1|	29.8	480	506	601	1.77e-49	178
k141_37261_7	SARG|NP_348076	27.3	685	706	652	1.32e-74	252
k141_37261_7	SARG|L42544.gene.p01	28.3	672	706	651	2.45e-72	246
k141_37261_7	SARG|YP_002850805	26.8	693	706	652	6.69e-72	245
k141_37261_7	SARG|AAV80410	27.4	668	706	651	2.42e-71	243
k141_37261_7	SARG|ZP_02952732	26.4	693	706	652	2.43e-70	241
k141_37261_7	SARG|ZP_02632674	26.4	693	706	660	2.84e-70	241
k141_37261_7	SARG|L20800.gene.p01	26.4	693	706	652	8.97e-70	239
k141_37261_7	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.4	671	706	639	1.91e-61	216
k141_37261_7	SARG|gi|544707441|ref|WP_021137831.1|	27.4	674	706	639	3.43e-60	213
k141_37261_7	SARG|AJ514254.gene.p01	26.8	699	706	640	4.81e-60	212
k141_37261_8	SARG|ACF08831	36.6	134	396	639	3.40e-16	79.3
k141_37261_8	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	37.6	133	396	639	6.05e-16	78.6
k141_124496_5	SARG|gb|AAK76137.1|ARO:3000024|patA	21.5	247	500	564	5.27e-08	54.3
k141_124496_5	SARG|gi|491465657|ref|WP_005323423.1|	36.4	55	500	513	1.41e-06	49.7
k141_124496_5	SARG|gi|951183771|ref|WP_057661487.1|	28.6	77	500	603	2.66e-06	48.9
k141_124496_5	SARG|AF170880.4.gene1.p01	25.1	179	500	615	2.68e-06	48.9
k141_124496_5	SARG|gi|558888514|ref|WP_023543283.1|	25.1	179	500	615	4.66e-06	48.1
k141_124496_5	SARG|gi|664170108|ref|WP_030704355.1|	28.9	76	500	603	6.10e-06	47.8
k141_124496_5	SARG|gi|501350226|ref|WP_012381861.1|	28.9	76	500	603	6.10e-06	47.8
k141_124496_5	SARG|gi|913055317|ref|WP_050357634.1|	28.9	76	500	603	6.10e-06	47.8
k141_124496_5	SARG|gi|948040364|ref|WP_056699531.1|	28.9	76	500	603	6.10e-06	47.8
k141_124496_5	SARG|gi|827013130|ref|WP_047175495.1|	28.9	76	500	603	6.10e-06	47.8
k141_19659_7	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.6	826	888	1024	1.59e-71	254
k141_19659_7	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.6	826	888	1024	1.59e-71	254
k141_19659_7	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.6	826	888	1024	2.93e-71	253
k141_19659_7	SARG|gb|CAA53189|ARO:3000521|mupA	24.6	826	888	1024	2.93e-71	253
k141_19659_9	SARG|gb|AAG05914|ARO:3004075|MuxC	25.1	894	1310	1036	4.96e-54	205
k141_19659_9	CARD|gb|AAC75137.1|ARO:3000794|mdtC	24.0	907	1310	1025	2.99e-51	196
k141_19659_9	SARG|gb|AAG05915.1|ARO:3004074|MuxB	24.5	877	1310	1043	2.28e-50	193
k141_19659_9	SARG|gb|CAH14033.1|ARO:3004100|LpeB	25.4	875	1310	1014	8.21e-50	191
k141_19659_9	CARD|gb|AAC75136.1|ARO:3000793|mdtB	23.8	878	1310	1040	1.96e-48	187
k141_19659_9	SARG|gb|BAE06006.1|ARO:3003705|mexN	25.6	817	1310	1036	9.49e-47	182
k141_19659_9	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	24.7	894	1310	1051	1.59e-45	178
k141_19659_9	SARG|gi|490805434|ref|WP_004667559.1|	24.2	916	1310	1063	2.36e-40	161
k141_19659_9	SARG|YP_348488	23.2	897	1310	1043	6.82e-40	160
k141_19659_9	SARG|gi|490802824|ref|WP_004664957.1|	24.2	916	1310	1063	7.09e-40	160
k141_27882_12	CARD|gb|BAB41874.1|ARO:3000815|mgrA	31.9	141	147	147	2.60e-25	93.2
k141_19918_10	SARG|gi|446573718|ref|WP_000651064.1|	26.4	444	445	451	1.70e-40	149
k141_19918_10	SARG|gi|686155635|ref|WP_031787393.1|	26.6	444	445	451	2.35e-40	149
k141_19918_10	SARG|gi|686432388|ref|WP_031921070.1|	26.6	440	445	451	2.35e-40	149
k141_19918_10	SARG|gi|1006223553|ref|WP_061745579.1|	26.5	438	445	451	3.25e-40	148
k141_19918_10	SARG|gi|686448604|ref|WP_031928572.1|	25.5	436	445	451	4.50e-40	148
k141_19918_10	SARG|ZP_03986195	26.4	440	445	451	6.22e-40	147
k141_19918_10	SARG|gi|516415429|ref|WP_017804827.1|	26.4	440	445	451	1.19e-39	147
k141_19918_10	SARG|gi|446573695|ref|WP_000651041.1|	26.4	440	445	451	1.19e-39	147
k141_19918_10	SARG|gi|686396521|ref|WP_031908504.1|	26.4	440	445	451	1.64e-39	146
k141_19918_10	SARG|gi|446573693|ref|WP_000651039.1|	26.4	440	445	451	1.64e-39	146
k141_28018_4	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.5	218	507	664	5.23e-14	73.6
k141_28018_4	SARG|gb|AAR96051.1|ARO:3002894|otrC	21.6	282	507	351	1.18e-11	65.1
k141_28018_4	SARG|gb|AAC75271.1|ARO:3003952|yojI	27.2	217	507	547	2.13e-11	65.1
k141_28018_4	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	21.2	288	507	351	3.73e-11	63.5
k141_28018_4	SARG|gi|817122037|ref|WP_046494699.1|	24.4	242	507	613	1.24e-10	62.8
k141_28018_4	SARG|gb|AAK76137.1|ARO:3000024|patA	26.1	253	507	564	1.55e-10	62.4
k141_28018_4	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	27.5	211	507	579	3.64e-10	61.2
k141_28018_4	SARG|gi|1033151784|ref|WP_064457526.1|	25.1	215	507	614	5.00e-10	60.8
k141_28018_4	SARG|gi|664304639|ref|WP_030834011.1|	25.1	215	507	614	5.00e-10	60.8
k141_28018_4	SARG|gi|1011069317|ref|WP_062010695.1|	25.1	215	507	614	5.00e-10	60.8
k141_28018_7	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	23.5	115	534	228	3.15e-07	50.4
k141_94200_8	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	48.1	231	231	233	7.28e-77	230
k141_94200_8	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	46.8	233	231	235	1.27e-75	227
k141_94200_8	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	46.2	234	231	239	1.44e-75	227
k141_94200_8	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	45.6	226	231	231	2.09e-73	221
k141_94200_8	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	44.5	229	231	229	1.59e-72	219
k141_94200_8	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.9	228	231	232	1.00e-71	217
k141_94200_8	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.9	228	231	232	1.00e-71	217
k141_94200_8	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	45.4	227	231	231	7.85e-71	215
k141_94200_8	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.4	227	231	231	7.85e-71	215
k141_94200_8	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	45.0	231	231	232	8.10e-71	215
k141_94200_9	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	30.9	259	675	357	1.64e-29	119
k141_94200_9	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	30.9	259	675	357	1.64e-29	119
k141_94200_9	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.3	300	675	370	1.53e-26	110
k141_94200_9	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.4	292	675	365	2.10e-25	107
k141_94200_9	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	28.7	254	675	392	2.44e-24	104
k141_94200_9	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.5	258	675	381	7.39e-23	100
k141_94200_9	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.5	258	675	381	7.39e-23	100
k141_94200_9	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.1	258	675	381	2.41e-22	98.6
k141_94200_9	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.1	258	675	381	2.41e-22	98.6
k141_94200_9	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.0	278	675	381	3.41e-21	95.1
k141_77678_4	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.0	642	651	655	7.57e-115	357
k141_77678_4	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.9	644	651	655	1.06e-114	357
k141_77678_4	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.2	642	651	655	1.50e-114	356
k141_77678_4	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.0	642	651	655	2.11e-114	356
k141_77678_4	SARG|gb|AKA86814|ARO:3003746|optrA	35.0	642	651	655	2.11e-114	356
k141_77678_4	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.0	642	651	655	2.96e-114	355
k141_77678_4	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.0	642	651	655	4.16e-114	355
k141_77678_4	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.0	642	651	655	4.16e-114	355
k141_77678_4	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.0	642	651	655	4.16e-114	355
k141_77678_4	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.0	642	651	655	4.16e-114	355
k141_77678_14	SARG|L42544.gene.p01	24.0	662	697	651	1.13e-48	180
k141_77678_14	SARG|AAV80410	24.0	662	697	651	1.13e-48	180
k141_77678_14	SARG|AJ514254.gene.p01	23.6	665	697	640	7.02e-43	163
k141_77678_14	SARG|gi|538450536|ref|WP_020998529.1|	23.5	673	697	639	7.04e-40	154
k141_77678_14	SARG|NC_002758.1120355.p01	23.3	694	697	639	1.28e-39	154
k141_77678_14	SARG|CAL69903	23.4	675	697	639	3.13e-39	152
k141_77678_14	SARG|ABB70053	23.4	675	697	639	5.68e-39	152
k141_77678_14	SARG|gi|446614384|ref|WP_000691730.1|	23.7	675	697	639	7.66e-39	151
k141_77678_14	SARG|Q54807	23.4	675	697	639	1.03e-38	151
k141_77678_14	SARG|ABB70047	23.4	675	697	639	1.03e-38	151
k141_5911_2	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	40.0	695	641	703	2.37e-145	437
k141_125282_4	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.7	254	418	355	1.21e-29	117
k141_125282_4	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	32.7	254	418	355	1.21e-29	117
k141_125282_4	SARG|ACM47285	32.7	254	418	363	1.37e-29	117
k141_125282_4	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.3	257	418	356	4.39e-29	115
k141_125282_4	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.2	258	418	356	6.04e-29	115
k141_125282_4	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.2	258	418	356	6.04e-29	115
k141_125282_4	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	31.5	254	418	355	1.42e-27	111
k141_125282_4	SARG|BAE96115	31.5	254	418	355	1.42e-27	111
k141_125282_4	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.3	258	418	346	4.40e-24	101
k141_125282_4	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	32.4	188	418	209	6.60e-21	89.4
k141_61171_6	SARG|gb|ANZ79476.1|ARO:3003908|Erm(47)	33.2	187	293	246	7.80e-24	96.3
k141_61171_6	SARG|L22689.1.gene1.p01	30.4	240	293	257	9.66e-24	96.3
k141_61171_6	SARG|gb|QQM99828.1|ARO:3007041|Erm(52)	33.5	182	293	309	8.57e-23	94.7
k141_61171_6	SARG|gb|CZT31773.1|ARO:3004094|Erm(48)	31.6	244	293	243	7.28e-22	90.9
k141_61171_6	NCBI|WP_052259183.1|1|1|erm(42)|erm(42)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN|LINCOSAMIDE/MACROLIDE|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(42)|AMR|multidrug	32.0	203	293	301	2.32e-19	85.1
k141_61171_6	megares|MEG_2781|Drugs|MLS|23S_rRNA_methyltransferases|ERM42_1	32.0	203	293	303	2.38e-19	85.1
k141_61171_6	SARG|gb|CBY77552.1|ARO:3003106|Erm(42)	32.0	203	293	301	4.38e-19	84.3
k141_61171_11	CARD|gb|BAB36671.1|ARO:3000832|evgA	22.8	206	208	204	3.19e-18	78.2
k141_61171_11	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.3	102	208	228	3.27e-13	65.1
k141_61171_13	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	32.9	316	314	343	1.51e-50	169
k141_61171_13	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	30.4	309	314	325	1.02e-45	156
k141_61171_13	SARG|gb|AAA26793|ARO:3003748|oleC	30.3	307	314	325	2.83e-45	155
k141_61171_13	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	31.8	314	314	307	7.95e-38	135
k141_61171_13	SARG|gb|ADZ12699.1|ARO:3005091|RanA	30.9	236	314	258	1.48e-26	104
k141_61171_13	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	30.0	237	314	351	3.72e-25	102
k141_61171_13	SARG|gb|AAR96051.1|ARO:3002894|otrC	30.0	237	314	351	5.12e-25	102
k141_61171_13	SARG|gb|AAK76137.1|ARO:3000024|patA	25.4	209	314	564	1.29e-14	73.2
k141_61171_13	SARG|gb|APB03219.1|ARO:3003986|TaeA	23.6	233	314	648	1.13e-06	48.9
k141_94450_5	CARD|gb|AAC16242.1|ARO:3005069|rsmA	51.9	54	73	61	7.70e-17	66.2
k141_77948_13	SARG|gi|851965596|ref|WP_048234849.1|	30.2	281	312	660	9.29e-42	152
k141_77948_13	SARG|gi|507086291|ref|WP_016157032.1|	31.3	281	312	660	9.29e-42	152
k141_77948_13	SARG|gi|1002399350|ref|WP_061382108.1|	30.2	281	312	660	9.29e-42	152
k141_77948_13	SARG|YP_002850217	29.9	281	312	660	4.55e-41	150
k141_77948_13	SARG|gi|507083067|ref|WP_016153816.1|	31.0	281	312	660	6.25e-41	149
k141_77948_13	SARG|gi|757799830|ref|WP_043017032.1|	29.5	281	312	660	8.58e-41	149
k141_77948_13	SARG|gi|696375142|ref|WP_032949690.1|	29.5	281	312	660	1.62e-40	148
k141_77948_13	SARG|gi|765458296|ref|WP_044714032.1|	29.5	281	312	660	2.22e-40	148
k141_77948_13	SARG|gi|851928593|ref|WP_048220996.1|	28.5	281	312	660	3.05e-40	147
k141_77948_13	SARG|gi|489117806|ref|WP_003027650.1|	29.5	281	312	660	3.05e-40	147
k141_77948_16	SARG|gb|BAH45481.1|ARO:3002815|clbB	32.3	331	359	343	4.28e-53	177
k141_77948_16	SARG|AXY65402.1	33.7	323	359	357	2.37e-52	176
k141_77948_18	CARD|gb|WKR28567.1|ARO:3007678|IreK	34.4	633	700	718	2.89e-97	314
k141_46601_2	SARG|gi|835233765|ref|WP_047410073.1|	53.2	218	230	648	1.28e-76	242
k141_46601_2	SARG|gi|754951242|ref|WP_042307417.1|	53.2	218	230	648	1.28e-76	242
k141_46601_2	SARG|gi|493734654|ref|WP_006683876.1|	53.2	218	230	648	1.28e-76	242
k141_46601_2	SARG|gi|851922185|ref|WP_048218206.1|	52.8	218	230	648	2.52e-76	241
k141_46601_2	SARG|gi|949718947|ref|WP_057063453.1|	52.8	218	230	648	2.52e-76	241
k141_46601_2	SARG|gi|696375069|ref|WP_032949617.1|	52.8	218	230	648	2.52e-76	241
k141_46601_2	SARG|gi|489127020|ref|WP_003036815.1|	52.8	218	230	648	2.52e-76	241
k141_46601_2	SARG|gi|803568669|ref|WP_046077412.1|	52.3	218	230	648	6.95e-76	240
k141_46601_2	SARG|gi|446110352|ref|WP_000188207.1|	52.3	218	230	648	6.95e-76	240
k141_46601_2	SARG|YP_002382193	52.3	218	230	648	6.95e-76	240
k141_46601_4	SARG|gb|AAV85982.1|ARO:3000535|macB	31.4	424	418	644	3.25e-45	164
k141_46601_4	SARG|gi|919910427|ref|WP_052906132.1|	29.3	420	418	648	8.42e-36	138
k141_46601_4	SARG|gi|487410704|ref|WP_001678420.1|	29.3	420	418	648	2.12e-35	137
k141_46601_4	SARG|gi|487359045|ref|WP_001634240.1|	29.0	420	418	648	2.89e-35	136
k141_46601_4	SARG|gi|485890120|ref|WP_001482667.1|	29.0	420	418	648	2.89e-35	136
k141_46601_4	SARG|gi|1001803476|ref|WP_061336327.1|	28.5	417	418	648	5.33e-35	135
k141_46601_4	SARG|gi|1016544759|ref|WP_063115144.1|	29.3	420	418	648	5.33e-35	135
k141_46601_4	SARG|gi|446110290|ref|WP_000188145.1|	29.0	420	418	648	7.25e-35	135
k141_46601_4	SARG|gi|654658955|ref|WP_028119847.1|	29.0	420	418	648	7.25e-35	135
k141_46601_4	SARG|gi|485866062|ref|WP_001464282.1|	29.0	420	418	648	7.25e-35	135
k141_46601_19	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	39.3	201	227	231	5.96e-42	141
k141_46601_19	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.6	221	227	219	9.55e-41	137
k141_46601_19	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	36.8	201	227	233	1.97e-40	137
k141_46601_19	SARG|ZP_02848503	34.7	225	227	221	2.39e-35	124
k141_46601_19	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.1	224	227	219	4.51e-35	123
k141_46601_19	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	33.5	200	227	225	1.47e-34	122
k141_46601_19	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.7	224	227	219	1.78e-34	121
k141_46601_19	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.7	224	227	220	1.82e-34	121
k141_46601_19	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.7	224	227	220	2.57e-34	121
k141_46601_19	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.3	229	227	220	1.42e-33	119
k141_46601_20	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	26.7	240	382	359	7.09e-17	80.1
k141_46601_20	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	25.3	237	382	364	8.54e-15	73.9
k141_46601_20	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	25.3	237	382	364	8.54e-15	73.9
k141_46601_20	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	24.2	227	382	364	5.20e-13	68.6
k141_46601_20	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	24.2	227	382	364	5.20e-13	68.6
k141_108260_5	CARD|gb|ATC67679.1|ARO:3000838|arlR	30.4	112	532	219	1.96e-08	53.9
k141_108260_5	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.2	117	532	231	1.89e-06	48.1
k141_78333_2	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	27.2	459	530	654	6.52e-36	140
k141_78333_2	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	27.2	459	530	670	7.14e-36	140
k141_78333_2	SARG|AAB51122	27.2	459	530	670	7.14e-36	140
k141_78333_2	SARG|Q08425	27.2	459	530	641	1.10e-35	140
k141_78333_2	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	27.2	459	530	657	1.21e-35	140
k141_78333_2	SARG|Z21523.gene.p01	27.2	459	530	657	1.21e-35	140
k141_78333_2	SARG|Q52360	25.8	454	530	641	1.66e-34	136
k141_78333_2	SARG|P70882	25.8	454	530	641	1.66e-34	136
k141_78333_2	SARG|BAD46890	25.8	454	530	657	1.81e-34	136
k141_78333_2	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.1	454	530	641	7.43e-34	134
k141_78333_6	SARG|FR772051.1.gene9.p01	21.0	219	380	524	7.31e-09	56.2
k141_78333_6	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	24.0	196	380	461	1.57e-08	55.1
k141_78333_6	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	24.9	169	380	461	4.70e-07	50.4
k141_78333_6	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	22.9	214	380	524	1.17e-06	49.3
k141_78333_6	SARG|gi|686436876|ref|WP_031922735.1|	21.3	197	380	491	6.15e-06	47.0
k141_78367_9	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	32.9	240	312	322	4.62e-26	104
k141_78367_9	SARG|NP_878015	33.3	240	312	322	4.47e-25	101
k141_78367_9	SARG|AAY52004	32.5	240	312	322	6.18e-25	101
k141_78367_9	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	31.5	235	312	351	9.37e-25	101
k141_78367_9	megares|MEG_7399|Drugs|Glycopeptide|VanA-type_resistance_protein|VANHA_1	32.7	223	312	237	1.80e-24	98.2
k141_78367_9	SARG|gb|AAB05626.1|ARO:3002943|vanHB	31.7	262	312	323	1.14e-23	97.8
k141_78367_9	SARG|gi|498515089|ref|WP_010815296.1|	31.7	262	312	323	2.17e-23	97.1
k141_78367_9	SARG|Q47748	31.7	262	312	323	2.17e-23	97.1
k141_78367_9	SARG|gi|985522333|ref|WP_060811962.1|	31.7	262	312	323	2.17e-23	97.1
k141_78367_9	SARG|KF478993.1.gene2.p01	32.4	238	312	350	3.12e-23	97.1
k141_117340_6	SARG|gi|1035706844|ref|WP_064548272.1|	29.0	131	947	648	3.63e-08	56.2
k141_94812_1	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	30.0	210	376	307	1.10e-21	93.2
k141_94812_1	SARG|P42332	27.8	205	376	306	5.18e-21	91.3
k141_94812_1	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	27.8	205	376	306	5.18e-21	91.3
k141_94812_1	SARG|gi|510143239|gb|AGN36970.1|	27.8	205	376	313	5.71e-21	91.3
k141_94812_1	SARG|ABB80128	28.4	201	376	306	7.08e-21	90.9
k141_94812_1	SARG|AAD21213	27.3	205	376	306	3.37e-20	89.0
k141_94812_1	SARG|gi|445996710|ref|WP_000074565.1|	28.8	205	376	309	8.92e-20	87.8
k141_94812_1	SARG|gi|445996719|ref|WP_000074574.1|	28.3	205	376	309	2.26e-19	86.7
k141_94812_1	SARG|gi|446026113|ref|WP_000103968.1|	26.3	205	376	306	1.02e-18	84.7
k141_94812_1	SARG|gi|500448961|gb|EOP61695.1|	27.8	205	376	306	1.39e-18	84.3
k141_94812_18	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.6	248	268	255	1.08e-22	92.8
k141_94812_18	SARG|gi|502669352|ref|WP_012905216.1|	28.3	237	268	648	4.91e-21	91.3
k141_94812_18	SARG|gi|803568669|ref|WP_046077412.1|	29.0	238	268	648	2.23e-20	89.4
k141_94812_18	SARG|gi|446110352|ref|WP_000188207.1|	29.0	238	268	648	2.23e-20	89.4
k141_94812_18	SARG|YP_002382193	29.0	238	268	648	2.23e-20	89.4
k141_94812_18	SARG|gi|803575554|ref|WP_046081557.1|	29.0	238	268	648	2.23e-20	89.4
k141_94812_18	SARG|gi|446110351|ref|WP_000188206.1|	29.0	238	268	648	2.23e-20	89.4
k141_94812_18	SARG|gi|1035706844|ref|WP_064548272.1|	28.5	242	268	648	5.06e-18	82.4
k141_94812_18	SARG|gi|1035670474|ref|WP_064517458.1|	27.7	242	268	648	6.84e-18	82.0
k141_94812_18	SARG|gi|1035717981|ref|WP_064557480.1|	27.7	242	268	648	6.84e-18	82.0
k141_61628_6	SARG|gi|663350985|ref|WP_030349761.1|	31.1	485	582	613	2.22e-66	226
k141_61628_6	SARG|AF170880.4.gene1.p01	30.8	491	582	615	3.21e-66	226
k141_61628_6	SARG|gi|558888514|ref|WP_023543283.1|	30.5	491	582	615	4.47e-66	225
k141_61628_6	SARG|gi|748767925|ref|WP_040019608.1|	31.5	485	582	623	1.94e-65	224
k141_61628_6	SARG|gi|926351744|ref|WP_053683383.1|	31.7	486	582	648	1.59e-64	222
k141_61628_6	SARG|gi|817122037|ref|WP_046494699.1|	30.7	492	582	613	3.05e-62	215
k141_61628_6	SARG|gi|953808775|ref|WP_058042812.1|	28.4	585	582	608	1.02e-60	211
k141_61628_6	SARG|gb|AAC74000.1|ARO:3003950|msbA	44.4	261	582	582	3.12e-58	203
k141_61628_6	SARG|gb|AAK76136.1|ARO:3000025|patB	29.8	483	582	588	4.69e-57	200
k141_61628_6	SARG|gi|1033151784|ref|WP_064457526.1|	28.1	502	582	614	3.54e-55	196
k141_61628_7	SARG|gi|497748188|ref|WP_010062372.1|	33.7	522	577	605	4.02e-73	244
k141_61628_7	SARG|gi|764446018|ref|WP_044369325.1|	33.5	522	577	605	7.82e-73	243
k141_61628_7	SARG|gi|664180077|ref|WP_030714054.1|	33.5	522	577	605	2.12e-72	242
k141_61628_7	SARG|gi|695887424|ref|WP_032788534.1|	33.5	523	577	605	4.13e-72	241
k141_61628_7	SARG|gi|951183771|ref|WP_057661487.1|	33.1	522	577	603	5.52e-72	241
k141_61628_7	SARG|gi|860594225|ref|WP_048475168.1|	33.0	527	577	620	7.89e-72	241
k141_61628_7	SARG|gi|695891735|ref|WP_032792824.1|	33.3	522	577	603	1.07e-71	240
k141_61628_7	SARG|gi|913055317|ref|WP_050357634.1|	33.3	522	577	603	1.50e-71	239
k141_61628_7	SARG|gi|948040364|ref|WP_056699531.1|	33.3	522	577	603	1.50e-71	239
k141_61628_7	SARG|gi|1045390184|ref|WP_065479071.1|	33.1	523	577	605	2.18e-71	239
k141_46997_12	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	44.9	236	241	229	2.08e-65	201
k141_46997_12	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.0	234	241	231	3.13e-65	201
k141_46997_12	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	44.5	238	241	232	1.49e-63	197
k141_46997_12	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.5	240	241	235	1.31e-62	194
k141_46997_12	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.7	234	241	232	2.40e-62	194
k141_46997_12	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	43.9	237	241	233	2.48e-62	194
k141_46997_12	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	43.0	237	241	232	9.65e-62	192
k141_46997_12	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.6	237	241	232	3.88e-61	191
k141_46997_12	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.6	237	241	232	5.49e-61	190
k141_46997_12	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.2	237	241	232	2.20e-60	189
k141_46997_13	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.0	258	491	354	1.77e-30	120
k141_46997_13	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.6	258	491	354	3.32e-30	119
k141_46997_13	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.8	258	491	352	4.39e-30	119
k141_46997_13	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	30.4	240	491	365	1.03e-29	118
k141_46997_13	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	32.6	227	491	367	1.06e-29	118
k141_46997_13	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	32.6	227	491	368	1.08e-29	118
k141_46997_13	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.9	270	491	370	1.11e-29	118
k141_46997_13	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.4	258	491	376	1.09e-28	115
k141_46997_13	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	31.4	258	491	376	1.09e-28	115
k141_46997_13	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.0	227	491	381	1.60e-28	115
k141_117599_9	SARG|gi|445996722|ref|WP_000074577.1|	30.8	117	178	309	1.15e-09	55.1
k141_117599_9	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	29.5	95	178	307	1.55e-09	54.7
k141_117599_9	SARG|gi|445996723|ref|WP_000074578.1|	29.9	117	178	309	1.56e-09	54.7
k141_117599_9	SARG|gi|507035724|ref|WP_016107411.1|	29.1	117	178	309	2.12e-09	54.3
k141_117599_9	SARG|gi|445996695|ref|WP_000074550.1|	29.1	117	178	309	2.12e-09	54.3
k141_117599_9	SARG|gi|445996698|ref|WP_000074553.1|	29.1	117	178	309	2.12e-09	54.3
k141_117599_9	SARG|gi|445996724|ref|WP_000074579.1|	29.9	117	178	309	2.88e-09	53.9
k141_117599_9	SARG|gi|884875933|emb|CKG93789.1|	29.9	117	178	309	2.88e-09	53.9
k141_117599_9	SARG|gi|445996719|ref|WP_000074574.1|	29.1	117	178	309	3.92e-09	53.5
k141_117599_9	SARG|gi|1043490477|ref|WP_065382463.1|	29.1	117	178	309	3.92e-09	53.5
k141_108757_13	SARG|gi|921979807|ref|WP_053271336.1|	29.7	239	326	648	5.80e-18	83.6
k141_108757_13	SARG|gb|AYV52072.1|ARO:3002882|lmrD	24.1	220	326	664	4.12e-08	53.5
k141_108757_13	SARG|gi|943938624|ref|WP_055567802.1|	25.1	223	326	602	1.65e-07	51.6
k141_108757_13	SARG|gi|501350226|ref|WP_012381861.1|	25.0	232	326	603	2.19e-07	51.2
k141_108757_13	SARG|gi|1045390184|ref|WP_065479071.1|	24.2	223	326	605	2.19e-07	51.2
k141_108757_13	SARG|gi|497748188|ref|WP_010062372.1|	24.2	223	326	605	2.92e-07	50.8
k141_108757_13	SARG|gi|664170108|ref|WP_030704355.1|	24.7	223	326	603	5.14e-07	50.1
k141_108757_13	SARG|gi|490068471|ref|WP_003970646.1|	24.7	223	326	603	5.14e-07	50.1
k141_108757_13	SARG|gi|695865802|ref|WP_032778631.1|	24.2	223	326	605	5.15e-07	50.1
k141_108757_13	SARG|gi|695887424|ref|WP_032788534.1|	24.2	223	326	605	6.84e-07	49.7
k141_85414_3	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	29.2	260	516	359	2.74e-26	108
k141_85414_3	SARG|gb|AAG05187.1|ARO:3005067|ParS	27.3	286	516	428	6.65e-26	108
k141_85414_3	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	32.9	237	516	354	2.17e-25	106
k141_85414_3	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	32.5	237	516	352	3.88e-25	105
k141_85414_3	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	32.5	237	516	376	5.44e-25	105
k141_85414_3	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	32.5	237	516	376	5.44e-25	105
k141_85414_3	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.6	242	516	354	9.99e-25	104
k141_85414_3	CARD|gb|AEX49906.1|ARO:3003583|basS	29.4	204	516	477	9.71e-22	97.1
k141_85414_3	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	30.6	252	516	364	2.91e-21	94.4
k141_85414_3	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	30.6	252	516	364	2.91e-21	94.4
k141_85421_4	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	34.8	221	241	225	4.48e-47	154
k141_85421_4	CARD|gb|AAC73788.1|ARO:3003841|kdpE	34.8	221	241	225	4.48e-47	154
k141_62027_1	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	27.4	175	460	481	4.82e-11	63.5
k141_62027_1	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	28.0	175	460	451	1.40e-10	62.0
k141_20968_3	SARG|gb|AML99881.1|ARO:3001327|mdtK	31.8	245	248	474	9.18e-28	109
k141_71016_2	SARG|gb|CAE00499.1|ARO:3003835|cdeA	27.8	418	433	441	3.15e-57	193
k141_71016_11	SARG|gb|APB03219.1|ARO:3003986|TaeA	49.0	669	654	648	8.95e-206	590
k141_71016_11	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	543	654	655	3.09e-65	226
k141_71016_11	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.3	542	654	655	8.18e-65	224
k141_71016_11	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.3	543	654	655	8.18e-65	224
k141_71016_11	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.3	543	654	655	1.13e-64	224
k141_71016_11	SARG|gb|AKA86814|ARO:3003746|optrA	29.3	543	654	655	1.13e-64	224
k141_71016_11	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.3	543	654	655	4.15e-64	223
k141_71016_11	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.3	543	654	655	4.15e-64	223
k141_71016_11	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.3	543	654	655	4.15e-64	223
k141_71016_11	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.3	543	654	655	4.15e-64	223
k141_6594_9	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	25.6	473	485	633	1.16e-15	78.6
k141_15374_13	SARG|gi|446573715|ref|WP_000651061.1|	25.1	442	456	451	3.56e-28	115
k141_15374_13	SARG|gi|763462741|ref|WP_044292157.1|	24.9	442	456	451	1.22e-27	113
k141_15374_13	SARG|gi|686390606|ref|WP_031905637.1|	24.9	442	456	451	1.22e-27	113
k141_15374_13	SARG|Q2G140	24.9	442	456	451	1.22e-27	113
k141_15374_13	SARG|gi|757671144|ref|WP_042903632.1|	24.9	442	456	451	1.65e-27	113
k141_15374_13	SARG|gi|727749287|ref|WP_033861814.1|	24.9	442	456	451	1.65e-27	113
k141_15374_13	SARG|gi|486215009|ref|WP_001556470.1|	24.9	442	456	451	1.65e-27	113
k141_15374_13	SARG|gi|686294396|ref|WP_031862836.1|	24.9	442	456	451	2.25e-27	112
k141_15374_13	SARG|gi|686334333|ref|WP_031881350.1|	24.9	442	456	451	4.15e-27	112
k141_15374_14	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	61.5	78	243	655	3.36e-24	99.8
k141_15374_14	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	61.5	78	243	655	3.36e-24	99.8
k141_15374_14	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	61.5	78	243	655	3.36e-24	99.8
k141_15374_14	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	60.3	78	243	655	3.86e-23	96.7
k141_15374_14	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	60.3	78	243	655	3.86e-23	96.7
k141_15374_14	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	60.3	78	243	655	3.86e-23	96.7
k141_15374_14	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	60.3	78	243	655	3.86e-23	96.7
k141_15374_14	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	60.3	78	243	655	3.86e-23	96.7
k141_15374_14	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	60.3	78	243	655	3.86e-23	96.7
k141_15374_14	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	60.3	78	243	655	3.86e-23	96.7
k141_15374_15	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	45.6	434	493	655	3.56e-125	378
k141_15374_15	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	45.6	434	493	655	3.56e-125	378
k141_15374_15	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	45.4	434	493	655	1.00e-124	377
k141_15374_15	SARG|gb|AKA86814|ARO:3003746|optrA	45.4	434	493	655	1.00e-124	377
k141_15374_15	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	45.4	434	493	655	2.81e-124	376
k141_15374_15	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	45.4	434	493	655	2.81e-124	376
k141_15374_15	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	45.4	434	493	655	2.81e-124	376
k141_15374_15	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	45.4	434	493	655	2.81e-124	376
k141_15374_15	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	45.2	434	493	655	7.89e-124	375
k141_15374_15	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	45.2	434	493	655	1.11e-123	374
k141_62444_10	SARG|AAD41881	32.8	131	388	323	2.92e-14	72.0
k141_62444_10	SARG|AAD42183	32.8	131	388	322	5.25e-14	71.2
k141_62444_10	SARG|AAD51059	32.8	131	388	323	5.29e-14	71.2
k141_62444_10	SARG|AAR37059	32.8	131	388	323	7.12e-14	70.9
k141_62444_10	SARG|AY082011.1.gene6.p01	36.4	129	388	323	2.33e-13	69.3
k141_62444_10	SARG|gi|552942232|ref|WP_023043160.1|	36.4	129	388	323	3.13e-13	68.9
k141_62444_10	SARG|YP_002333394	34.7	118	388	323	1.83e-12	66.6
k141_62444_10	SARG|AF310956.2.gene5.p01	33.9	118	388	323	5.92e-12	65.1
k141_62444_10	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	33.9	118	388	323	5.92e-12	65.1
k141_62444_10	SARG|gb|AAB05626.1|ARO:3002943|vanHB	33.1	118	388	323	5.92e-12	65.1
k141_54483_15	CARD|gb|ADM92605.1|ARO:3000553|adeR	29.0	124	565	247	3.67e-09	56.6
k141_54483_15	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	27.9	129	565	232	1.84e-08	54.3
k141_54483_15	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	29.0	107	565	231	3.50e-07	50.4
k141_54483_15	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	27.1	107	565	231	2.05e-06	48.1
k141_54483_27	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	26.7	206	313	722	1.62e-17	82.0
k141_29265_3	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	38.8	477	473	481	3.96e-94	292
k141_29265_3	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.8	473	473	451	5.18e-93	288
k141_29265_3	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	37.9	475	473	451	5.00e-90	280
k141_102071_1	CARD|gb|ABD30512.1|ARO:3000839|arlS	30.0	243	438	451	2.36e-29	118
k141_102071_1	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.7	218	438	381	9.93e-25	103
k141_102071_1	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.7	218	438	381	9.93e-25	103
k141_102071_1	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.1	225	438	381	1.84e-24	103
k141_102071_1	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.1	225	438	381	1.84e-24	103
k141_102071_1	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.7	225	438	381	3.40e-24	102
k141_102071_1	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.7	225	438	381	3.40e-24	102
k141_102071_1	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	29.1	237	438	392	9.69e-24	101
k141_102071_1	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.7	225	438	381	1.16e-23	100
k141_102071_1	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.7	225	438	381	1.16e-23	100
k141_102071_2	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	40.3	233	224	230	1.18e-46	153
k141_102071_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.2	229	224	231	3.44e-46	152
k141_102071_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.2	229	224	231	3.44e-46	152
k141_102071_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.2	232	224	232	5.61e-45	149
k141_102071_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.2	232	224	232	5.61e-45	149
k141_102071_2	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	38.9	229	224	231	7.70e-45	148
k141_102071_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.8	226	224	219	8.73e-44	145
k141_102071_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.4	231	224	229	4.59e-43	144
k141_102071_2	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.9	229	224	231	9.66e-43	143
k141_102071_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.0	229	224	231	1.36e-42	142
k141_102071_5	SARG|gi|817122037|ref|WP_046494699.1|	31.3	233	251	613	4.56e-23	96.7
k141_102071_5	SARG|gi|953808775|ref|WP_058042812.1|	32.1	218	251	608	8.35e-23	95.9
k141_102071_5	SARG|gi|505420018|ref|WP_015607120.1|	29.7	222	251	603	1.13e-22	95.5
k141_102071_5	SARG|gi|558888514|ref|WP_023543283.1|	31.3	224	251	615	2.10e-22	94.7
k141_102071_5	SARG|gi|948137056|ref|WP_056795395.1|	30.9	220	251	602	2.81e-22	94.4
k141_102071_5	SARG|AF170880.4.gene1.p01	30.8	224	251	615	5.23e-22	93.6
k141_102071_5	SARG|gi|739906046|ref|WP_037756452.1|	32.7	220	251	620	5.26e-22	93.6
k141_102071_5	SARG|gi|748767925|ref|WP_040019608.1|	30.6	232	251	623	5.27e-22	93.6
k141_102071_5	SARG|gi|516574297|ref|WP_017949361.1|	32.7	220	251	620	7.13e-22	93.2
k141_102071_5	SARG|gi|947982677|ref|WP_056642336.1|	30.2	222	251	626	7.16e-22	93.2
k141_102513_2	SARG|gi|542061059|gb|ERI11611.1|	38.0	163	175	316	3.69e-22	89.7
k141_102513_2	SARG|gi|445996708|ref|WP_000074563.1|	36.8	163	175	309	1.26e-20	85.5
k141_102513_2	SARG|P42332	36.8	163	175	306	1.68e-20	85.1
k141_102513_2	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	36.8	163	175	306	1.68e-20	85.1
k141_102513_2	SARG|gi|510143239|gb|AGN36970.1|	36.8	163	175	313	1.83e-20	85.1
k141_102513_2	SARG|YP_001373621	35.0	163	175	318	2.68e-20	84.7
k141_102513_2	SARG|ABB80128	36.8	163	175	306	3.25e-20	84.3
k141_102513_2	SARG|gi|488130770|ref|WP_002201978.1|	36.2	163	175	309	4.66e-20	84.0
k141_102513_2	SARG|gi|447195835|ref|WP_001273091.1|	36.2	163	175	306	6.25e-20	83.6
k141_102513_2	SARG|gi|445996732|ref|WP_000074587.1|	35.0	163	175	309	6.47e-20	83.6
k141_55361_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	46.1	178	182	231	2.89e-55	173
k141_55361_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	45.3	181	182	232	4.43e-52	165
k141_55361_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	45.3	181	182	232	4.43e-52	165
k141_55361_1	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	47.0	181	182	233	2.59e-51	163
k141_55361_1	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	43.9	180	182	231	4.90e-51	162
k141_55361_1	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.9	180	182	231	4.90e-51	162
k141_55361_1	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	43.8	176	182	229	1.86e-50	161
k141_55361_1	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.3	180	182	231	2.78e-50	160
k141_55361_1	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.3	180	182	231	3.94e-50	160
k141_55361_1	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	45.8	179	182	232	4.06e-50	160
k141_55361_35	SARG|DQ212986.1.gene3.p01	50.7	67	74	75	8.41e-19	71.6
k141_22731_21	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	28.4	317	510	447	4.51e-28	115
k141_22731_21	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.4	317	510	447	2.06e-27	113
k141_22731_21	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.4	317	510	447	2.06e-27	113
k141_22731_21	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.4	317	510	447	2.06e-27	113
k141_22731_21	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	26.8	317	510	454	6.09e-26	109
k141_22731_21	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	25.0	220	510	392	4.74e-22	97.1
k141_22731_21	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	22.6	243	510	364	3.29e-19	88.2
k141_22731_21	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	22.6	243	510	364	3.29e-19	88.2
k141_22731_21	CARD|gb|ADM92606.1|ARO:3000549|adeS	22.2	311	510	361	4.29e-19	87.8
k141_22731_21	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	23.9	201	510	359	2.48e-18	85.5
k141_22731_22	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.0	228	229	232	8.62e-57	179
k141_22731_22	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.0	228	229	232	8.62e-57	179
k141_22731_22	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.0	231	229	232	1.11e-54	174
k141_22731_22	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.4	230	229	231	2.45e-53	170
k141_22731_22	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	40.2	229	229	230	5.40e-52	167
k141_22731_22	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.8	228	229	231	4.44e-51	164
k141_22731_22	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.8	228	229	231	4.44e-51	164
k141_22731_22	CARD|gb|AAD51348.1|ARO:3003066|smeR	39.5	223	229	229	4.74e-50	162
k141_22731_22	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.5	228	229	231	5.02e-50	162
k141_22731_22	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	40.4	228	229	231	1.00e-49	161
k141_22731_37	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	38.7	313	328	343	5.05e-73	228
k141_22731_37	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	38.1	318	328	348	5.84e-73	228
k141_22731_37	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	38.3	311	328	337	3.37e-72	226
k141_22731_37	SARG|KF478993.1.gene2.p01	38.2	285	328	350	3.48e-72	226
k141_22731_37	SARG|DQ018711.1.gene4.p01	36.4	324	328	322	3.86e-70	220
k141_22731_37	SARG|gi|737310392|ref|WP_035293250.1|	36.4	324	328	323	6.29e-69	217
k141_22731_37	SARG|FJ349556.1.gene5.p01	35.8	318	328	326	1.53e-67	213
k141_22731_37	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	36.0	314	328	351	2.21e-67	214
k141_22731_37	SARG|gi|746609237|ref|WP_039635344.1|	36.8	310	328	322	2.72e-67	213
k141_22731_37	SARG|NP_878015	35.0	320	328	322	3.84e-67	212
k141_22939_2	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	54.0	1230	1287	1162	0.0	1222
k141_22939_2	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	51.8	1236	1287	1186	0.0	1166
k141_22939_2	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	51.8	1236	1287	1186	0.0	1166
k141_110430_10	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	35.5	591	597	579	9.36e-102	319
k141_110430_10	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	35.4	591	597	579	1.02e-100	316
k141_110430_10	SARG|gb|AAK76136.1|ARO:3000025|patB	34.2	532	597	588	3.34e-92	294
k141_110430_10	SARG|gi|917127754|ref|WP_051734466.1|	33.0	584	597	620	4.05e-91	292
k141_110430_10	SARG|gi|799286378|ref|WP_045936958.1|	32.9	584	597	620	1.56e-90	291
k141_110430_10	SARG|gi|926294973|ref|WP_053631154.1|	32.9	584	597	620	1.56e-90	291
k141_110430_10	SARG|gi|917203192|ref|WP_051809904.1|	32.4	584	597	620	2.19e-90	290
k141_110430_10	SARG|gi|926356413|ref|WP_053687351.1|	32.9	584	597	620	2.19e-90	290
k141_110430_10	SARG|gi|926345639|ref|WP_053677539.1|	32.9	584	597	620	2.19e-90	290
k141_110430_10	SARG|gi|926376632|ref|WP_053705806.1|	32.7	584	597	620	6.04e-90	289
k141_110430_11	SARG|gb|AAK76137.1|ARO:3000024|patA	32.2	552	587	564	6.85e-83	269
k141_110430_11	SARG|gi|663330365|ref|WP_030329892.1|	31.5	534	587	607	3.78e-82	268
k141_110430_11	SARG|gi|662175949|ref|WP_030118884.1|	31.3	534	587	605	7.06e-82	267
k141_110430_11	SARG|gi|664556405|ref|WP_031071225.1|	31.5	553	587	602	9.21e-82	267
k141_110430_11	SARG|gi|663155409|ref|WP_030194633.1|	31.3	534	587	605	9.88e-82	267
k141_110430_11	SARG|gi|664538723|ref|WP_031054357.1|	31.3	534	587	605	9.88e-82	267
k141_110430_11	SARG|gi|926286457|ref|WP_053623344.1|	31.3	534	587	605	1.38e-81	266
k141_110430_11	SARG|gi|648667297|ref|WP_026359044.1|	31.3	552	587	605	1.93e-81	266
k141_110430_11	SARG|gi|664194237|ref|WP_030727956.1|	31.3	534	587	605	1.93e-81	266
k141_110430_11	SARG|gi|664317010|ref|WP_030845774.1|	31.3	534	587	605	2.71e-81	266
k141_87391_3	SARG|gi|446048013|ref|WP_000125868.1|	30.9	223	514	648	2.32e-25	108
k141_87391_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.9	223	514	664	2.33e-14	74.7
